PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
2775304-0	1989	The specificity of inhibition of debrisoquine 4-hydroxylase activity by quinidine and quinine in the rat is the inverse of that in man.	Quinine	86-93	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	33-59
2775304-1	1989	The kinetics of inhibition of debrisoquine 4-hydroxylase activity by quinidine and quinine in rat and human liver microsomes have been compared.	Quinine	83-90	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	30-56
2775304-7	1989	Inhibition of debrisoquine 4-hydroxylase activity by both quinine and quinidine in human and rat liver is competitive.	Quinine	58-65	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	14-40
2775304-10	1989	Although both quinidine and quinine are competitive inhibitors of debrisoquine 4-hydroxylase activity in rat and man, their potency is reversed.	Quinine	28-35	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	66-92
3055451-4	1988	Most of the remaining patients showed a significant fall in plasma glucose (P less than 0.05), but not to the hypoglycaemic range, and an increase in plasma insulin after quinine (P less than 0.01).	Quinine	171-178	insulin	Homo sapiens	157-164
2765911-7	1989	NPY also significantly inhibited the intake of water flavored with 8% sucrose and 0.1% quinine.	Quinine	87-94	neuropeptide Y	Rattus norvegicus	0-3
2550246-10	1989	Fc gamma RII expression was found to be enhanced during the G1 phase of the cell cycle since (a) only large cells (i.e. those that had entered the G1 phase) expressed an increased amount of Fc gamma RII and (b) blocking the entry of activated cells into the S phase (with the ion channel blocker quinine) did not affect the Fc gamma RII induction by LPS.	Quinine	296-303	Fc receptor, IgG, low affinity IIb	Mus musculus	0-12
3215010-5	1988	In Experiment 5, SLA animals showed greater stress-induced suppression of drinking a weak quinine solution than SHA animals.	Quinine	90-97	src-like adaptor	Rattus norvegicus	17-20
3130251-1	1987	The activity of hepatic aldehyde oxidase from rabbit, guinea pig, rat, marmoset, dog, baboon and man was investigated in vitro with charged and uncharged N-heterocyclic substrates: Km and Vmax values were determined for phthalazine, 6,7-dimethoxy-1-[-4-(ethylcarbamoyloxy)piperidino]phthalazine (carbazeran), quinine and quinidine.	Quinine	309-316	aldehyde oxidase 1	Homo sapiens	24-40
3818954-0	1987	Binding of quinine- and quinidine-dependent drug antibodies to platelets is mediated by the Fab domain of the immunoglobulin G and is not Fc dependent.	Quinine	11-18	FA complementation group B	Homo sapiens	92-95
3330586-2	1987	From these findings and a review of 10 case reports, we propose that disopyramide causes hypoglycaemia by stimulation of insulin release as described for the antimalarial drugs quinine and quinidine.	Quinine	177-184	insulin	Homo sapiens	121-128
3117315-6	1987	The three infusions of quinine increased plasma insulin concentrations in a similar way.	Quinine	23-30	insulin	Homo sapiens	48-55
3497888-1	1987	Effect of pyrimethamine, an antimalarial antifolate, and of mefloquine, chloroquine, and quinine, which belong to the quinoline group of antimalarials, on proliferation and interleukin 2 (IL-2) production of human lymphocytes was studied in vitro.	Quinine	89-96	interleukin 2	Homo sapiens	173-186
3497888-1	1987	Effect of pyrimethamine, an antimalarial antifolate, and of mefloquine, chloroquine, and quinine, which belong to the quinoline group of antimalarials, on proliferation and interleukin 2 (IL-2) production of human lymphocytes was studied in vitro.	Quinine	89-96	interleukin 2	Homo sapiens	188-192
2439690-7	1987	Quinine, an inhibitor of Ca2+-activated K+ channels, abolished both Ca2+- and calmodulin-induced hyperpolarizations.	Quinine	0-7	calmodulin 2	Mus musculus	78-88
6115784-11	1981	SRIF-induced enhancement of 86Rb efflux was antagonized by TEA or quinine.	Quinine	66-73	somatostatin	Mus musculus	0-4
2425353-8	1986	The potassium channel blocker quinine inhibited cell growth and the synthesis of p52 and p36 when added 0 or 2 hr after rIL-2 stimulation but not when added 6 hr after rIL-2 stimulation.	Quinine	30-37	interleukin 2	Rattus norvegicus	120-125
2425353-9	1986	Thus, a quinine-sensitive event occurring in L2 cells between 2 and 6 hr after rIL-2 stimulation is necessary for synthesis of type II proteins, DNA synthesis, and cell proliferation.	Quinine	8-15	interleukin 2	Rattus norvegicus	79-84
6343877-6	1983	In seven healthy fasting volunteers intravenous quinine increased the mean plasma insulin concentration (+/- S.D.)	Quinine	48-55	insulin	Homo sapiens	82-89
6847709-3	1983	Phospholipase A2 inhibitors, such as quinacrine, chloroquine, quinine and p-bromophenacyl bromide, all inhibited the secretion of catecholamines evoked by carbamylcholine in a dose-dependent manner.	Quinine	62-69	LOC104974671	Bos taurus	0-16
33704459-9	2021	RESULTS: After QHCl alone, there were effects of treatment, but not route of administration, on C-peptide, GLP-1, and glucose (P < 0.05); QHCl stimulated C-peptide and GLP-1 and lowered glucose concentrations (IG control: 4.5 +- 0.1; IG-QHCl: 3.9 +- 0.1; ID-control: 4.6 +- 0.1; ID-QHCl: 4.2 +- 0.1 mmol/L) compared with control.	Quinine	138-142	glucagon like peptide 1 receptor	Homo sapiens	168-173
179586-6	1976	Finally it was observed that, like the prolactin effect, the phospholipase A effect was abolished by incubation with dibutyryl cyclic AMP, theophylline, quinine, indomethacin and prostaglandin E1.	Quinine	153-160	prolactin	Mus musculus	39-48
179586-6	1976	Finally it was observed that, like the prolactin effect, the phospholipase A effect was abolished by incubation with dibutyryl cyclic AMP, theophylline, quinine, indomethacin and prostaglandin E1.	Quinine	153-160	phospholipase A and acyltransferase 1	Mus musculus	61-76
33704459-1	2021	BACKGROUND: In preclinical studies, bitter compounds, including quinine, stimulate secretion of glucoregulatory hormones [e.g., glucagon-like peptide-1 (GLP-1)] and slow gastric emptying, both key determinants of postprandial glycemia.	Quinine	64-71	glucagon like peptide 1 receptor	Homo sapiens	153-158
6271829-3	1981	The release reaction could be antagonized by phospholipase A2 inhibitors such as quinacrine and quinine, suggesting that THC can stimulate the activity of this enzyme.	Quinine	96-103	phospholipase A2 group IB	Homo sapiens	45-61
946356-2	1976	Effects of quinine and chloroquine on the sheep ERG.	Quinine	11-18	transcriptional regulator ERG	Ovis aries	48-51
33918670-6	2021	In human Caco-2 colon epithelial cells as well as the lung cell line A549 stably expressing ACE2 and TMPRSS2, quinine also showed antiviral activity.	Quinine	110-117	angiotensin converting enzyme 2	Homo sapiens	92-96
33918670-6	2021	In human Caco-2 colon epithelial cells as well as the lung cell line A549 stably expressing ACE2 and TMPRSS2, quinine also showed antiviral activity.	Quinine	110-117	transmembrane serine protease 2	Homo sapiens	101-108
33704459-9	2021	RESULTS: After QHCl alone, there were effects of treatment, but not route of administration, on C-peptide, GLP-1, and glucose (P < 0.05); QHCl stimulated C-peptide and GLP-1 and lowered glucose concentrations (IG control: 4.5 +- 0.1; IG-QHCl: 3.9 +- 0.1; ID-control: 4.6 +- 0.1; ID-QHCl: 4.2 +- 0.1 mmol/L) compared with control.	Quinine	138-142	insulin	Homo sapiens	154-163
33704459-9	2021	RESULTS: After QHCl alone, there were effects of treatment, but not route of administration, on C-peptide, GLP-1, and glucose (P < 0.05); QHCl stimulated C-peptide and GLP-1 and lowered glucose concentrations (IG control: 4.5 +- 0.1; IG-QHCl: 3.9 +- 0.1; ID-control: 4.6 +- 0.1; ID-QHCl: 4.2 +- 0.1 mmol/L) compared with control.	Quinine	138-142	insulin	Homo sapiens	154-163
33704459-9	2021	RESULTS: After QHCl alone, there were effects of treatment, but not route of administration, on C-peptide, GLP-1, and glucose (P < 0.05); QHCl stimulated C-peptide and GLP-1 and lowered glucose concentrations (IG control: 4.5 +- 0.1; IG-QHCl: 3.9 +- 0.1; ID-control: 4.6 +- 0.1; ID-QHCl: 4.2 +- 0.1 mmol/L) compared with control.	Quinine	138-142	glucagon like peptide 1 receptor	Homo sapiens	168-173
33704459-11	2021	QHCl stimulated C-peptide and GLP-1, slowed gastric emptying, and reduced glucose (IG control: 7.2 +- 0.3; IG-QHCl: 6.2 +- 0.3; ID-control: 7.2 +- 0.3; ID-QHCl: 6.4 +- 0.4 mmol/L)  compared with control.	Quinine	0-4	insulin	Homo sapiens	16-25
33704459-11	2021	QHCl stimulated C-peptide and GLP-1, slowed gastric emptying, and reduced glucose (IG control: 7.2 +- 0.3; IG-QHCl: 6.2 +- 0.3; ID-control: 7.2 +- 0.3; ID-QHCl: 6.4 +- 0.4 mmol/L)  compared with control.	Quinine	0-4	glucagon like peptide 1 receptor	Homo sapiens	30-35
33704459-12	2021	CONCLUSIONS: In healthy men, IG and ID quinine administration similarly lowered plasma glucose, increased plasma insulin and GLP-1, and slowed gastric emptying.	Quinine	39-46	glucagon like peptide 1 receptor	Homo sapiens	125-130
33160072-11	2021	We also measured intake of sucrose, quinine, and water after CNO treatment and found that increasing NAc core activity via CNO/hM3Dq increased quinine intake, and increased water intake over time.	Quinine	143-150	biogenesis of lysosomal organelles complex-1, subunit 4, cappuccino	Mus musculus	61-64
33160072-11	2021	We also measured intake of sucrose, quinine, and water after CNO treatment and found that increasing NAc core activity via CNO/hM3Dq increased quinine intake, and increased water intake over time.	Quinine	143-150	biogenesis of lysosomal organelles complex-1, subunit 4, cappuccino	Mus musculus	123-126
32544510-3	2020	We previously showed that drinking under a moderate-challenge, quinine-alcohol model (Alc-ModQ) shows less variable responding in many measures, suggesting a more automatic strategy to overcome challenge.	Quinine	63-70	allantoicase	Homo sapiens	86-89
33527681-3	2021	It has been shown that rats having reduced levels of expression of the gamma-aminobutyric acid (GABA) transporter, GAT-3, in the amygdala tend to persist in seeking and drinking alcohol even when adulterated with quinine, suggesting that pharmacological interventions aimed at restoring GABA homeostasis in these individuals may provide a targeted treatment to limit compulsive alcohol drinking.	Quinine	213-220	solute carrier family 6 member 11	Rattus norvegicus	71-120
33105624-5	2020	Here, we show that the genetic deletion of Hcn1 causes an increase in alcohol preference on intermittent 2-bottle choice task in homozygous null (HCN1-/-) male mice compared to wild-type littermates without affecting saccharine or quinine preference.	Quinine	231-238	hyperpolarization activated cyclic nucleotide gated potassium channel 1	Mus musculus	43-47
31658255-3	2019	Mutant worms that lack the electrical synapse proteins INX-18 and INX-19 become hypersensitive to dilute quinine.	Quinine	105-112	Innexin	Caenorhabditis elegans	55-61
32415404-4	2020	Two-bottle choice model showed that the overexpression of MMP-9 in the hippocampus developed by adeno-associated virus (AAV) could decrease alcohol consumption and preference, but did not affect taste preference, which was tested using saccharin or quinine solutions.	Quinine	249-256	matrix metallopeptidase 9	Homo sapiens	58-63
31565732-2	2020	METHODS: In this study, we investigated the capacity for quinine hydrochloride (Q-HCL) to enhance the antimicrobial effects of antimicrobial blue light ([aBL] 405 nm wavelength) against multidrug-resistant (MDR) Gram-negative bacteria in vitro and in vivo.	Quinine	80-85	c-abl oncogene 1, non-receptor tyrosine kinase	Mus musculus	154-157
31565732-3	2020	RESULTS: Our findings demonstrated the significant improvement in the inactivation of MDR Pseudomonas aeruginosa and Acinetobacter baumannii (planktonic cells and biofilms) when aBL was illuminated during Q-HCL exposure.	Quinine	205-210	c-abl oncogene 1, non-receptor tyrosine kinase	Mus musculus	178-181
31565732-4	2020	Furthermore, the addition of Q-HCL significantly potentiated the antimicrobial effects of aBL in a mouse skin abrasion infection model.	Quinine	29-34	c-abl oncogene 1, non-receptor tyrosine kinase	Mus musculus	90-93
31888655-12	2019	The risk of recurrences within 28 days after hospital admission was 1.94 times higher (95% CI aHR 1.57-2.39, p &lt; 0.0001) in patients receiving intravenous quinine with follow on oral quinine treatment than in patients treated with DHP after intravenous artesunate therapy.	Quinine	158-165	dihydropyrimidinase	Homo sapiens	234-237
32385839-0	2020	Pyrroloquinoline Quinine and LY294002 Changed Cell Cycle and Apoptosis by Regulating PI3K-AKT-GSK3beta Pathway in SH-SY5Y Cells.	Quinine	17-24	AKT serine/threonine kinase 1	Homo sapiens	90-93
32385839-0	2020	Pyrroloquinoline Quinine and LY294002 Changed Cell Cycle and Apoptosis by Regulating PI3K-AKT-GSK3beta Pathway in SH-SY5Y Cells.	Quinine	17-24	glycogen synthase kinase 3 alpha	Homo sapiens	94-102
32413538-3	2020	For examples, amino acid derivatives such as gamma-aminobutyric acid (GABA) and Nalpha,Nalpha-bis(carboxymethyl)-L-Lysine (BCML) blocked responses to quinine mediated by human TAS2R4.	Quinine	150-157	taste 2 receptor member 4	Homo sapiens	176-182
31960754-7	2020	These results provide new pharmacological evidence that ALP facilitates neuroprotection via prevention of neuronal oxidative stress and promotion of cell survival signaling pathways.Abbreviations: ABTS: 2,2"-azino-bis-(3-ethylbenzothiazoline-6-sulfonicacid); AD: Alzheimer"s disease; ALP: polysaccharide extracts isolated from Annona muricata leaves; ARE: antioxidant response element; DPPH: 1,1-diphenyl-picrylhydrazyl; DCFH-DA: 2",7"-dichlorofluorescin diacetate; ECL: electrochemiluminescence; ERK: extracellular regulated kinase; FBS: Fetal bovine serum; FITC: fluorescein isothiocyanate; FRAP: ferric reducing antioxidant power; HO-1: Heme oxygenase-1; JNK: c-jun N-terminal kinase; MAPKs: mitogen-activated protein kinases; MDA: malondialdehyde; MMP: mitochondrial membrane potential; MTT: 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide; NQO1: NAD(P)H:quinine oxidoreductase 1, Nrf2: nuclear factor-E2-related factor 2; PD: parkinson"s disease; PI3K: phosphatidylinositol-3kinase; PVDF: polyvinylidene difluoride; ROS: reactive oxygen species; SOD: Superoxidedismutase; TPTZ: tripydyltriazine.	Quinine	871-878	alopecia, recessive	Mus musculus	56-59
32252371-4	2020	Under streptozotocin (STZ)-induced diabetes mellites (DM) conditions, the protein expression levels of T1R2 and T1R3 in CP were higher than those under control conditions, and these DM rats exhibited increased lick ratios in a low sucrose concentration range in a brief access test with a mixture of sucrose and quinine hydrochloride (QHCl).	Quinine	335-339	taste 1 receptor member 3	Rattus norvegicus	112-116
31608921-2	2019	As potential cancer biomarkers, nitroreductase (NTR) and human quinine oxidoreductase 1 (hNQO1) are overexpressed in many type of cancer cells.	Quinine	63-70	NAD(P)H quinone dehydrogenase 1	Homo sapiens	89-94
31658255-3	2019	Mutant worms that lack the electrical synapse proteins INX-18 and INX-19 become hypersensitive to dilute quinine.	Quinine	105-112	Innexin-19	Caenorhabditis elegans	66-72
31658255-4	2019	Cell-specific rescue experiments indicate that inx-18 operates in ASK while inx-19 is required in both ASK and ASH for proper quinine sensitivity.	Quinine	126-133	Innexin-19	Caenorhabditis elegans	76-82
31658255-6	2019	While inx-18 and inx-19 mutant animals have a similar behavioral phenotype, several lines of evidence suggest the proteins encoded by these genes play different roles in modulating the aversive quinine response.	Quinine	194-201	Innexin	Caenorhabditis elegans	6-12
31658255-6	2019	While inx-18 and inx-19 mutant animals have a similar behavioral phenotype, several lines of evidence suggest the proteins encoded by these genes play different roles in modulating the aversive quinine response.	Quinine	194-201	Innexin-19	Caenorhabditis elegans	17-23
31632299-8	2019	Although the promiscuous TAS2R agonists, quinine and denatonium, inhibited the LPS-induced release of TNF-alpha, CCL3 and CXCL8, diphenidol was inactive.	Quinine	41-48	tumor necrosis factor	Homo sapiens	102-111
31632299-8	2019	Although the promiscuous TAS2R agonists, quinine and denatonium, inhibited the LPS-induced release of TNF-alpha, CCL3 and CXCL8, diphenidol was inactive.	Quinine	41-48	C-C motif chemokine ligand 3	Homo sapiens	113-117
31632299-8	2019	Although the promiscuous TAS2R agonists, quinine and denatonium, inhibited the LPS-induced release of TNF-alpha, CCL3 and CXCL8, diphenidol was inactive.	Quinine	41-48	C-X-C motif chemokine ligand 8	Homo sapiens	122-127
31509959-7	2019	Calcium release from HEK293T cells stably expressing the T2R4 human bitter taste receptor was significantly (p < 0.05) attenuated by BPAH-AGEs (up to 96%) and BPCH-AGEs (up to 92%) when compared to the BPAH (62%) and BPCH (3%) or quinine (0%).	Quinine	230-237	taste 2 receptor member 4	Homo sapiens	57-61
31500210-3	2019	We assessed multiple clinical relationships of ABCB1 activity-ex vivo drug resistance, gene expression, and the ABCB1 inhibitor quinine were evaluated.	Quinine	128-135	ATP binding cassette subfamily B member 1	Homo sapiens	112-117
30945322-5	2019	CYP3A activity was assessed using quinine as a probe before and during erlotinib treatment.	Quinine	34-41	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	0-5
31035086-0	2019	Protective effects of pyrroloquinoline quinine against oxidative stress-induced cellular senescence and inflammation in human renal tubular epithelial cells via Keap1/Nrf2 signaling pathway.	Quinine	39-46	kelch like ECH associated protein 1	Homo sapiens	161-166
30266601-7	2019	Interestingly, mice with activated LHA Nts neurons drank any fluid that was provided regardless of its palatability, but if given a choice they preferred water or palatable solutions over unpalatable (quinine) or dehydrating (hypertonic saline) solutions.	Quinine	201-208	neurotensin	Mus musculus	39-42
31032878-5	2019	EXPERIMENTAL APPROACH: We analysed sensitivity of recombinant Kv 12.1 channels to quinine, a substituted quinoline that blocks Kv 10.1 and Kv 11.1 at low micromolar concentrations.	Quinine	82-89	potassium voltage-gated channel subfamily H member 2	Homo sapiens	139-146
31032878-8	2019	Low sensitivity of Kv 12.1 and characteristics of quinine-dependent inhibition were determined by histidine 462, as site-directed mutagenesis of this residue into the homologous tyrosine of Kv 11.1 conferred Kv 11.1-like quinine block to Kv 12.1(H462Y).	Quinine	50-57	potassium voltage-gated channel subfamily H member 2	Homo sapiens	190-197
31032878-8	2019	Low sensitivity of Kv 12.1 and characteristics of quinine-dependent inhibition were determined by histidine 462, as site-directed mutagenesis of this residue into the homologous tyrosine of Kv 11.1 conferred Kv 11.1-like quinine block to Kv 12.1(H462Y).	Quinine	50-57	potassium voltage-gated channel subfamily H member 2	Homo sapiens	208-215
31032878-8	2019	Low sensitivity of Kv 12.1 and characteristics of quinine-dependent inhibition were determined by histidine 462, as site-directed mutagenesis of this residue into the homologous tyrosine of Kv 11.1 conferred Kv 11.1-like quinine block to Kv 12.1(H462Y).	Quinine	221-228	potassium voltage-gated channel subfamily H member 2	Homo sapiens	190-197
31032878-8	2019	Low sensitivity of Kv 12.1 and characteristics of quinine-dependent inhibition were determined by histidine 462, as site-directed mutagenesis of this residue into the homologous tyrosine of Kv 11.1 conferred Kv 11.1-like quinine block to Kv 12.1(H462Y).	Quinine	221-228	potassium voltage-gated channel subfamily H member 2	Homo sapiens	208-215
31032878-10	2019	In contrast, more favourable interactions can explain the higher quinine sensitivity of Kv 12.1(H462Y) and Kv 11.1 channels.	Quinine	65-72	potassium voltage-gated channel subfamily H member 2	Homo sapiens	107-114
31035086-0	2019	Protective effects of pyrroloquinoline quinine against oxidative stress-induced cellular senescence and inflammation in human renal tubular epithelial cells via Keap1/Nrf2 signaling pathway.	Quinine	39-46	NFE2 like bZIP transcription factor 2	Homo sapiens	167-171
30849122-9	2019	Citrulline injected ip on day 4 PI with quinine-injected ip on day 6 PI partially protected mice from eCM; citrulline plus scavenging of superoxide with pegylated superoxide dismutase and pegylated catalase protected all recipients from eCM.	Quinine	40-47	catalase	Mus musculus	198-206
31141679-3	2019	Gr32a is a gustatory chemoreceptor that, in D. melanogaster, is essential to inhibit interspecies courtship and sense quinine.	Quinine	118-125	Gustatory receptor 32a	Drosophila melanogaster	0-5
31141679-4	2019	Similar to D. melanogaster, we find that D. simulans Gr32a is expressed in foreleg tarsi, sensorimotor appendages that inhibit interspecies courtship, and it is required to sense quinine.	Quinine	179-186	Gustatory receptor 32a	Drosophila melanogaster	53-58
31117121-6	2019	The effects of extra- and intracellular acid and alkaline loading were abolished by quinine, a pan-selective inhibitor of two-pore domain potassium (K2P) channels, and suppressed by shRNA-mediated downregulation of the mechanosensitive K2P channel TREK-1.	Quinine	84-91	potassium two pore domain channel subfamily K member 2	Homo sapiens	248-254
30446509-6	2018	Pressure stimuli, arachidonic acid, and TREK-1 activators hyperpolarize these cells, effects that are antagonized by quinine, amlodipine, spadin, and short-hairpin RNA-mediated knockdown of TREK-1 but not TASK-1.	Quinine	117-124	potassium two pore domain channel subfamily K member 2	Homo sapiens	40-46
29286872-4	2019	Binding of the sensitizing drug, such as quinine, to GPIX has been proposed but is yet to be established.	Quinine	41-48	glycoprotein IX platelet	Homo sapiens	53-57
29286872-5	2019	This work demonstrates that quinine is retained specifically by human GPIX.	Quinine	28-35	glycoprotein IX platelet	Homo sapiens	70-74
29286872-6	2019	Quinine binding was first analyzed in wild-type mouse platelets and in transgenic mouse platelet expressing human GPIX using high performance liquid chromatography.	Quinine	0-7	glycoprotein IX platelet	Homo sapiens	114-118
29286872-7	2019	Binding of quinine to GPIX was then measured in Chinese hamster ovary (CHO) cells expressing a combination of wild type, human or mouse, three human/mouse chimeric constructs and six mutant GPIX proteins.	Quinine	11-18	glycoprotein IX platelet	Homo sapiens	22-26
29286872-7	2019	Binding of quinine to GPIX was then measured in Chinese hamster ovary (CHO) cells expressing a combination of wild type, human or mouse, three human/mouse chimeric constructs and six mutant GPIX proteins.	Quinine	11-18	glycoprotein 9 (platelet)	Mus musculus	190-194
29286872-8	2019	Quinine was retained by human GPIX.	Quinine	0-7	glycoprotein IX platelet	Homo sapiens	30-34
29286872-10	2019	The quinine binding site was mapped to residues 110-115 of human GPIX suggesting that quinine interacts with specific residues of the GP.	Quinine	4-11	glycoprotein IX platelet	Homo sapiens	65-69
29286872-10	2019	The quinine binding site was mapped to residues 110-115 of human GPIX suggesting that quinine interacts with specific residues of the GP.	Quinine	86-93	glycoprotein IX platelet	Homo sapiens	65-69
30592786-9	2019	KEY RESULTS: hOCT1 overexpression enhanced sorafenib, but not regorafenib, quinine-inhibitable uptake by hepatoma cells.	Quinine	75-82	solute carrier family 22 member 1	Homo sapiens	13-18
31091986-5	2019	In brain slices from lactating rats, application of quinine (0.1 mM), a selective blocker of Cx36, significantly reduced dye coupling among OT neurons as well as the discharge/firing frequency of spikes/action potentials and their amplitude, and transiently depolarized the membrane potential of OT neurons in whole-cell patch-clamp recordings.	Quinine	52-59	gap junction protein, delta 2	Rattus norvegicus	93-97
31091986-8	2019	Lastly, Western blotting analysis revealed that the presence of combined, but not alone, quinine and OT significantly reduced the amount of Cx36 in the SON.	Quinine	89-96	gap junction protein, delta 2	Rattus norvegicus	140-144
29701767-7	2018	Two-bottle preference tests, however, revealed that Rgs21-null mice have blunted aversion to quinine and denatonium, and blunted preference for monosodium glutamate, the sweeteners sucrose and SC45647, and (surprisingly) NaCl.	Quinine	93-100	regulator of G-protein signalling 21	Mus musculus	52-57
30333484-4	2018	In contrast, high concentrations of quinine are decoded by a high-threshold, slow-inactivation glutamate receptor GLR-5 in AIB.	Quinine	36-43	GLutamate Receptor family (AMPA)	Caenorhabditis elegans	114-119
29941014-2	2018	Associations of CYP3A4-mediated metabolism of quinine, with inflammatory biomarkers were investigated in patients undergoing maintenance hemodialysis (HD).	Quinine	46-53	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	16-22
28220535-6	2017	Subsequent concentration-inhibition curves revealed the antihistaminic prodrug loratadine (Ki  = 1.16 muM) and the antimalarial drug quinine (Ki  = 2.03 muM) to be the most potent SV2A protein ligands of the investigated drug library.	Quinine	133-140	synaptic vesicle glycoprotein 2A	Homo sapiens	180-184
29410428-3	2018	Here, we show that this conserved protein (PF3D7_0629500 in Plasmodium falciparum; AAT1 in P. chabaudi) is a structural homologue of the yeast amino acid transporter Tat2p, which is known to mediate quinine uptake and toxicity.	Quinine	199-206	aromatic amino acid transmembrane transporter TAT2	Saccharomyces cerevisiae S288C	166-171
29410428-7	2018	Like Tat2p, PF3D7_0629500-dependent quinine hypersensitivity was suppressible with tryptophan, consistent with a common transport mechanism.	Quinine	36-43	aromatic amino acid transmembrane transporter TAT2	Saccharomyces cerevisiae S288C	5-10
29311514-5	2018	From taste sensor measurements, diphenidol, haloperidol, diphenhydramine, dextromethorphan and papaverine, all ligands of hTAS2R 10 and/or hTAS2R14, were predicted to express strong bitterness, surpassing that of quinine.	Quinine	213-220	taste 2 receptor member 10	Homo sapiens	122-131
29311514-5	2018	From taste sensor measurements, diphenidol, haloperidol, diphenhydramine, dextromethorphan and papaverine, all ligands of hTAS2R 10 and/or hTAS2R14, were predicted to express strong bitterness, surpassing that of quinine.	Quinine	213-220	taste 2 receptor member 14	Homo sapiens	139-147
29372031-1	2018	Objectives: In the present study, a new series of 6-methoxy-2-arylquinoline analogues was designed and synthesized as P-glycoprotein (P-gp) inhibitors using quinine and flavones as the lead compounds.	Quinine	157-164	ATP binding cassette subfamily B member 1	Homo sapiens	118-132
29372031-1	2018	Objectives: In the present study, a new series of 6-methoxy-2-arylquinoline analogues was designed and synthesized as P-glycoprotein (P-gp) inhibitors using quinine and flavones as the lead compounds.	Quinine	157-164	ATP binding cassette subfamily B member 1	Homo sapiens	134-138
29688449-4	2018	CD-1 mice could readily use vapor cues from quinine hydrochloride, denatonium benzoate (DB), and 6-propyl-2-thiouracil to avoid their taste.	Quinine	44-65	CD1 antigen complex	Mus musculus	0-4
29383190-10	2017	Ki-67 and Cyclin D expression were significantly increased in primary Oct3-/- hepatocytes after treatment with the OCT inhibitors quinine or verapamil (p&lt;0.05).	Quinine	130-137	solute carrier family 22 (organic cation transporter), member 3	Mus musculus	70-74
29383190-11	2017	Functional inhibition of OCT by quinine resulted in an activation of c-Jun N-terminal kinase (Jnk), especially in Oct3-/- hepatocytes.	Quinine	32-39	solute carrier family 22 (organic cation transporter), member 3	Mus musculus	114-118
28828525-0	2017	Maternal consumption of quinine-containing sodas may induce G6PD crises in breastfed children.	Quinine	24-31	glucose-6-phosphate dehydrogenase	Homo sapiens	60-64
28828525-3	2017	We here report three cases of initial G6PD crises in breastfed children secondary to maternal consumption of a tonic drink which contains quinine.	Quinine	138-145	glucose-6-phosphate dehydrogenase	Homo sapiens	38-42
28828525-5	2017	CONCLUSION: The amount of quinine that is transmitted through breast milk appears to be sufficient to induce G6PD crises in breastfed children.	Quinine	26-33	glucose-6-phosphate dehydrogenase	Homo sapiens	109-113
28828525-9	2017	What is New:   Maternal consumption of tonic drink which contains quinine appears to be sufficient to induce G6PD crises in breastfed children.	Quinine	66-73	glucose-6-phosphate dehydrogenase	Homo sapiens	109-113
28811548-8	2017	Next, the ggTas2r1 structural model was successfully used to identify three quinine analogues (epiquinidine, ethylhydrocupreine, quinidine) as new ggTas2r1 agonists.	Quinine	76-83	taste 2 receptor member 40	Gallus gallus	10-18
28811548-8	2017	Next, the ggTas2r1 structural model was successfully used to identify three quinine analogues (epiquinidine, ethylhydrocupreine, quinidine) as new ggTas2r1 agonists.	Quinine	76-83	taste 2 receptor member 40	Gallus gallus	147-155
28347660-4	2017	Quinidine exhibited stronger inhibition than quinine; however, these two compounds inhibited the CYP2D6.10-mediated reaction more weakly than the CYP2D6.1 and CYP2D6.2 reactions.	Quinine	45-52	cytochrome P450, family 2, subfamily d, polypeptide 4	Rattus norvegicus	97-103
28347660-4	2017	Quinidine exhibited stronger inhibition than quinine; however, these two compounds inhibited the CYP2D6.10-mediated reaction more weakly than the CYP2D6.1 and CYP2D6.2 reactions.	Quinine	45-52	cytochrome P450, family 2, subfamily d, polypeptide 4	Rattus norvegicus	146-152
28347660-4	2017	Quinidine exhibited stronger inhibition than quinine; however, these two compounds inhibited the CYP2D6.10-mediated reaction more weakly than the CYP2D6.1 and CYP2D6.2 reactions.	Quinine	45-52	cytochrome P450, family 2, subfamily d, polypeptide 4	Rattus norvegicus	146-152
28220535-9	2017	The anti-convulsive effects of the natural product quinine may - at least in part - be explained by interaction with SV2A.	Quinine	51-58	synaptic vesicle glycoprotein 2A	Homo sapiens	117-121
27306084-8	2016	We also compared the consequence of OxtR modulation on the consumption and preference of saccharin and quinine and found that the two experimental groups did not differ for any tastant.	Quinine	103-110	oxytocin receptor	Mus musculus	36-40
28109977-4	2017	In normal control animals, intraoral application of 1mM quinine caused increased numbers of c-Fos-immunoreactive (c-Fos-IR) neurons in the external lateral subnucleus and external medial subnucleus of the PBN (elPBN and emPBN, respectively) compared with application of distilled water.	Quinine	56-63	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	92-97
28109977-4	2017	In normal control animals, intraoral application of 1mM quinine caused increased numbers of c-Fos-immunoreactive (c-Fos-IR) neurons in the external lateral subnucleus and external medial subnucleus of the PBN (elPBN and emPBN, respectively) compared with application of distilled water.	Quinine	56-63	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	114-119
27108691-0	2016	Facilitation of Hippocampal Kindling and Exacerbation of Kindled Seizures by Intra-CA1 Injection of Quinine: A Possible Role of Cx36 Gap Junctions.	Quinine	100-107	carbonic anhydrase 1	Rattus norvegicus	83-86
27108691-0	2016	Facilitation of Hippocampal Kindling and Exacerbation of Kindled Seizures by Intra-CA1 Injection of Quinine: A Possible Role of Cx36 Gap Junctions.	Quinine	100-107	gap junction protein, delta 2	Rattus norvegicus	128-132
27108691-3	2016	METHODS: Quinine, as the specific blocker of Cx36, was injected into CA1, and kindled seizures severity was examined 10 min afterward.	Quinine	9-16	gap junction protein, delta 2	Rattus norvegicus	45-49
27108691-3	2016	METHODS: Quinine, as the specific blocker of Cx36, was injected into CA1, and kindled seizures severity was examined 10 min afterward.	Quinine	9-16	carbonic anhydrase 1	Rattus norvegicus	69-72
27108691-4	2016	Moreover, quinine was injected into CA1 once daily, and the rate of CA1 kindling was recorded.	Quinine	10-17	carbonic anhydrase 1	Rattus norvegicus	36-39
27618912-2	2016	However, both CQ and QN are considered effective, although perhaps moderate inhibitors of CYP2D6, an enzyme now regarded as necessary for primaquine (PQ) pharmacologic activity.	Quinine	21-23	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	90-96
27690007-0	2016	Stereoselective Blockage of Quinidine and Quinine in the hERG Channel and the Effect of Their Rescue Potency on Drug-Induced hERG Trafficking Defect.	Quinine	42-49	ETS transcription factor ERG	Homo sapiens	57-61
27690007-4	2016	The aim of our research is to study and compare the impacts of quinidine and quinine on hERG.	Quinine	77-84	ETS transcription factor ERG	Homo sapiens	88-92
27690007-5	2016	Results show that both drugs block the hERG channel, with quinine 14-fold less potent than quinidine.	Quinine	58-65	ETS transcription factor ERG	Homo sapiens	39-43
27690007-9	2016	The mutation decreases affinity of the two drugs with hERG, and quinine was more potent than quinidine in F656C-hERG blockage.	Quinine	64-71	ETS transcription factor ERG	Homo sapiens	54-58
27690007-9	2016	The mutation decreases affinity of the two drugs with hERG, and quinine was more potent than quinidine in F656C-hERG blockage.	Quinine	64-71	ETS transcription factor ERG	Homo sapiens	112-116
27690007-13	2016	Our research demonstrated stereoselective effects of quinidine and quinine on the hERG channel, and this is the first study to explore their reversal potency on drug-induced hERG deficiency.	Quinine	67-74	ETS transcription factor ERG	Homo sapiens	82-86
27690007-13	2016	Our research demonstrated stereoselective effects of quinidine and quinine on the hERG channel, and this is the first study to explore their reversal potency on drug-induced hERG deficiency.	Quinine	67-74	ETS transcription factor ERG	Homo sapiens	174-178
27618912-5	2016	RESULTS: Both CQ and QN significantly inhibited the activity of CYP2D6.	Quinine	21-23	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	64-70
27618912-7	2016	CYP2D6-mediated hydroxylation was largely suppressed by both CQ and QN.	Quinine	68-70	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	0-6
27430155-6	2016	Quinine, a natural alkaloid that is well-known for its therapeutic treatment of malaria, exhibited a distinct antiproliferative and pro-apoptotic effect in HeLa and A549 tumor cell lines via the inhibition of the antiapoptotic protein, B-cell lymphoma (BCL)-2, and activation of the pro-apoptotic factor, BCL-2-associated X protein.	Quinine	0-7	BCL2 apoptosis regulator	Homo sapiens	236-259
27288892-9	2016	Interestingly, cholesterol sensitivity of T2R4 was observed at quinine concentrations in the lower mM range.	Quinine	63-70	taste 2 receptor member 4	Homo sapiens	42-46
26045093-0	2015	Mechanism of inhibition of mouse Slo3 (KCa 5.1) potassium channels by quinine, quinidine and barium.	Quinine	70-77	potassium channel, subfamily U, member 1	Mus musculus	33-37
26693810-3	2016	METHODS: Forty-three patients with CML were phenotyped for CYP3A activity using quinine as a probe drug and evaluated for clinical response parameters.	Quinine	80-87	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	59-64
26692363-6	2015	Intra-gastric treatment of obese WT and alpha-gust-/- mice with the bitter agonists denatonium benzoate (DB) or quinine (Q) during 4 weeks resulted in an alpha-gustducin-dependent decrease in body weight gain associated with a decrease in food intake (DB), but not involving major changes in gut peptide release.	Quinine	112-119	guanine nucleotide binding protein, alpha transducing 3	Mus musculus	154-169
26045093-0	2015	Mechanism of inhibition of mouse Slo3 (KCa 5.1) potassium channels by quinine, quinidine and barium.	Quinine	70-77	potassium calcium-activated channel subfamily U member 1	Homo sapiens	39-46
26045093-1	2015	BACKGROUND AND PURPOSE: The Slo3 (KCa 5.1) channel is a major component of mammalian KSper (sperm potassium conductance) channels and inhibition of these channels by quinine and barium alters sperm motility.	Quinine	166-173	potassium calcium-activated channel subfamily U member 1	Homo sapiens	28-32
26045093-1	2015	BACKGROUND AND PURPOSE: The Slo3 (KCa 5.1) channel is a major component of mammalian KSper (sperm potassium conductance) channels and inhibition of these channels by quinine and barium alters sperm motility.	Quinine	166-173	potassium calcium-activated channel subfamily U member 1	Homo sapiens	34-41
26045093-10	2015	CONCLUSIONS AND IMPLICATIONS: Block of mSlo3 channels by quinine, quinidine and barium is not state-dependent.	Quinine	57-64	potassium channel, subfamily U, member 1	Mus musculus	39-44
25604941-7	2015	T1R1 knockout mice readily learned the aversion to dashi and generalized the aversion to sucrose, citric acid, and quinine but not to NaCl, glutamate, or any amino acid.	Quinine	115-122	taste receptor, type 1, member 1	Mus musculus	0-4
24668578-6	2015	The EROD activity increased significantly following LB cells exposure to RA and HC (p&lt;0.05) but the expression of CYP1A1 protein was reduced by these drugs, whereas the expression of CYP1A1 protein and EROD activity decreased significantly following the addition of CA and QN (p&lt;0.05, p&lt;0.01).	Quinine	276-278	cytochrome P450, family 1, subfamily a, polypeptide 1	Rattus norvegicus	117-123
24668578-6	2015	The EROD activity increased significantly following LB cells exposure to RA and HC (p&lt;0.05) but the expression of CYP1A1 protein was reduced by these drugs, whereas the expression of CYP1A1 protein and EROD activity decreased significantly following the addition of CA and QN (p&lt;0.05, p&lt;0.01).	Quinine	276-278	cytochrome P450, family 1, subfamily a, polypeptide 1	Rattus norvegicus	186-192
25036266-7	2014	Chloroquine, denatonium, dextromethorphan, noscapine and quinine, agonists for TAS2R3, TAS2R4, TAS2R10 and TAS2R14, induced strong endothelium-independent relaxations (responses between 82-96% of maximal relaxations) in phenylephrine pre-contracted guinea-pig aorta that persisted in the presence of L-type Ca2+ and KCa1.1-channel blockers.	Quinine	57-64	taste 2 receptor member 3	Homo sapiens	79-85
25378213-7	2014	AC5 KO mice showed aversive behaviors to bitter tasting quinine, but they compulsively chose quinine-containing AC5 KO-pellets over fresh pellets.	Quinine	56-63	adenylate cyclase 5	Mus musculus	0-3
25378213-7	2014	AC5 KO mice showed aversive behaviors to bitter tasting quinine, but they compulsively chose quinine-containing AC5 KO-pellets over fresh pellets.	Quinine	93-100	adenylate cyclase 5	Mus musculus	0-3
25378213-7	2014	AC5 KO mice showed aversive behaviors to bitter tasting quinine, but they compulsively chose quinine-containing AC5 KO-pellets over fresh pellets.	Quinine	93-100	adenylate cyclase 5	Mus musculus	112-115
25036266-7	2014	Chloroquine, denatonium, dextromethorphan, noscapine and quinine, agonists for TAS2R3, TAS2R4, TAS2R10 and TAS2R14, induced strong endothelium-independent relaxations (responses between 82-96% of maximal relaxations) in phenylephrine pre-contracted guinea-pig aorta that persisted in the presence of L-type Ca2+ and KCa1.1-channel blockers.	Quinine	57-64	taste 2 receptor member 4	Homo sapiens	87-93
25036266-7	2014	Chloroquine, denatonium, dextromethorphan, noscapine and quinine, agonists for TAS2R3, TAS2R4, TAS2R10 and TAS2R14, induced strong endothelium-independent relaxations (responses between 82-96% of maximal relaxations) in phenylephrine pre-contracted guinea-pig aorta that persisted in the presence of L-type Ca2+ and KCa1.1-channel blockers.	Quinine	57-64	taste 2 receptor member 10	Homo sapiens	95-102
25036266-7	2014	Chloroquine, denatonium, dextromethorphan, noscapine and quinine, agonists for TAS2R3, TAS2R4, TAS2R10 and TAS2R14, induced strong endothelium-independent relaxations (responses between 82-96% of maximal relaxations) in phenylephrine pre-contracted guinea-pig aorta that persisted in the presence of L-type Ca2+ and KCa1.1-channel blockers.	Quinine	57-64	taste 2 receptor member 14	Homo sapiens	107-114
23532667-9	2013	In cells expressing functional OCT1 variants, OCT1 inhibition with quinine prevented sorafenib-induced toxicity.	Quinine	67-74	solute carrier family 22 member 1	Homo sapiens	31-35
25134447-8	2014	RESULTS: The behavioral follow up of the mice in an IntelliCage system revealed that Car6-/- mice preferred 3 muM quinine (bitter) solution, whereas wild type mice preferred water.	Quinine	114-121	carbonic anhydrase 6	Mus musculus	85-89
24161619-6	2014	Furthermore, SERT mutations known to decrease the binding affinity of many antidepressants affected the cinchona alkaloids in a stereo-specific manner where the similar inhibitory profiles for quinine and cinchonidine (8S,9R) were distinct from quinidine and cinchonine (8R,9S).	Quinine	193-200	solute carrier family 6 member 4	Homo sapiens	13-17
24161619-7	2014	Small molecule docking studies with hSERT homology models predict that quinine and cinchonidine bind to the central 5-HT binding site (S1) whereas quinidine and cinchonine bind to the S2 site.	Quinine	71-78	solute carrier family 6 member 4	Homo sapiens	36-41
22781839-4	2013	Using short hairpin RNA (shRNA)-expressing lentiviral vectors (LV) to alter locally the activity of mGluR7 in male rats, we have shown that blocking mGluR7 expression increased ethanol consumption and preference in a two-bottle choice drinking paradigm with no effect either on saccharin or on quinine used for taste discrimination.	Quinine	294-301	glutamate receptor, ionotropic, kainate 3	Mus musculus	149-155
23532667-9	2013	In cells expressing functional OCT1 variants, OCT1 inhibition with quinine prevented sorafenib-induced toxicity.	Quinine	67-74	solute carrier family 22 member 1	Homo sapiens	46-50
23532667-10	2013	Expression of OCT1 variants in Xenopus laevis oocytes and determination of quinine-sensitive sorafenib uptake by high-performance liquid chromatography-dual mass spectrometry confirmed that OCT1 is able to transport sorafenib and that R61S fs*10 and C88A fs*16 abolish this ability.	Quinine	75-82	solute carrier family 22 member 1	Homo sapiens	190-194
26417230-9	2013	Blockade of Cx36 GJs coupling and consequent disruption of inhibitory transmission in GABAergic interneurons in CA1 area seems to be responsible for the antiepileptogenic effect of quinine.	Quinine	181-188	carbonic anhydrase 1	Rattus norvegicus	112-115
23336807-0	2013	Ambient UVA-induced expression of p53 and apoptosis in human skin melanoma A375 cell line by quinine.	Quinine	93-100	tumor protein p53	Homo sapiens	34-37
26417230-0	2013	Blocking of rat hippocampal Cx36 by quinine accelerates kindling epileptogenesis.	Quinine	36-43	gap junction protein, delta 2	Rattus norvegicus	28-32
21303656-11	2011	The functional assays showed an increase in intracellular calcium levels after the application of exogenous ligands for T2R4, denatonium benzoate and quinine to these cultured cells, suggesting that endogenous T2R4 expressed in these cells is functional.	Quinine	150-157	taste 2 receptor member 4	Homo sapiens	210-214
26417230-4	2013	We investigated effect of quinine, a specific blocker of Cx36, on the seizure severity and epileptogenesis in amygala kindling model of epilepsy in rats.	Quinine	26-33	gap junction protein, delta 2	Rattus norvegicus	57-61
26417230-5	2013	Quinine (1, 50, 100, 500 and 2000 microM/rat) was injected directly into the CA1 and kindled seizure parameters including behavioral seizure stage, duration of evoked afterdischarges, and duration of generalized seizures behavior were recorded 10 min afterward.	Quinine	0-7	carbonic anhydrase 1	Rattus norvegicus	77-80
26417230-6	2013	Moreover, quinine (1, 30, and 100 microM/rat) was injected intra CA1 once daily during kindling development.	Quinine	10-17	carbonic anhydrase 1	Rattus norvegicus	65-68
26417230-9	2013	Blockade of Cx36 GJs coupling and consequent disruption of inhibitory transmission in GABAergic interneurons in CA1 area seems to be responsible for the antiepileptogenic effect of quinine.	Quinine	181-188	gap junction protein, delta 2	Rattus norvegicus	12-16
23458200-5	2013	Treatment of dissociated testes with carbenoxolone, a nonspecific blocker of gap junctional coupling, significantly reduced testosterone output as did treatment with quinine, which disrupts coupling provided by connexin36 and connexin45 gap junctions but not those composed of connexin43, indicating that either or both of connexins 36 and 45 could be involved in supporting Leydig cell steroidogenesis.	Quinine	166-173	gap junction protein, delta 2	Mus musculus	211-221
23458200-5	2013	Treatment of dissociated testes with carbenoxolone, a nonspecific blocker of gap junctional coupling, significantly reduced testosterone output as did treatment with quinine, which disrupts coupling provided by connexin36 and connexin45 gap junctions but not those composed of connexin43, indicating that either or both of connexins 36 and 45 could be involved in supporting Leydig cell steroidogenesis.	Quinine	166-173	gap junction protein, gamma 1	Mus musculus	226-236
23458200-5	2013	Treatment of dissociated testes with carbenoxolone, a nonspecific blocker of gap junctional coupling, significantly reduced testosterone output as did treatment with quinine, which disrupts coupling provided by connexin36 and connexin45 gap junctions but not those composed of connexin43, indicating that either or both of connexins 36 and 45 could be involved in supporting Leydig cell steroidogenesis.	Quinine	166-173	gap junction protein, alpha 1	Mus musculus	277-287
22420923-15	2012	Of 14 participants who provided additional information regarding their use of quinine, eight had a current prescription of quinine for muscle cramp at the time of the survey.	Quinine	123-130	cathelicidin antimicrobial peptide	Homo sapiens	142-147
22420923-19	2012	Most people who were taking quinine for muscle cramp were unaware that the Australian Therapeutic Goods Administration withdrew support of quinine for muscle cramp in 2004 due to the risk of thrombocytopaenia.	Quinine	28-35	cathelicidin antimicrobial peptide	Homo sapiens	47-52
22420923-19	2012	Most people who were taking quinine for muscle cramp were unaware that the Australian Therapeutic Goods Administration withdrew support of quinine for muscle cramp in 2004 due to the risk of thrombocytopaenia.	Quinine	139-146	cathelicidin antimicrobial peptide	Homo sapiens	158-163
21854775-6	2011	Artemisinin, primaquine, and quinine down-regulated GTP-cyclohydrolase 1 gene expression 1.26-, 1.29-, and 1.63-fold, respectively.	Quinine	29-36	GTP cyclohydrolase 1	Homo sapiens	52-72
23394313-3	2013	Quinine is an in vitro inhibitor of Trpm5, a cation channel expressed in taste bud cells, the gastrointestinal tract and pancreas.	Quinine	0-7	transient receptor potential cation channel, subfamily M, member 5	Mus musculus	36-41
23394313-8	2013	There was a trend for a diet-genotype interaction for body weight and body weight gain, with the effect of quinine less pronounced in the Trpm5 KO than in the WT background.	Quinine	107-114	transient receptor potential cation channel, subfamily M, member 5	Mus musculus	138-143
23394313-11	2013	A partial contribution of Trpm5 to quinine dependent body weight control is suggested.	Quinine	35-42	transient receptor potential cation channel, subfamily M, member 5	Mus musculus	26-31
23874221-3	2013	C. elegans lacking EGL-4 function are hypersensitive in their behavioral response to low concentrations of the bitter tastant quinine and exhibit an elevated calcium flux in the ASH sensory neurons in response to quinine.	Quinine	126-133	cGMP-dependent protein kinase;cGMP-dependent protein kinase egl-4	Caenorhabditis elegans	19-24
23874221-3	2013	C. elegans lacking EGL-4 function are hypersensitive in their behavioral response to low concentrations of the bitter tastant quinine and exhibit an elevated calcium flux in the ASH sensory neurons in response to quinine.	Quinine	213-220	cGMP-dependent protein kinase;cGMP-dependent protein kinase egl-4	Caenorhabditis elegans	19-24
23874221-5	2013	Our data suggest that activated EGL-4 dampens quinine sensitivity via phosphorylation and activation of the regulator of G protein signaling (RGS) proteins RGS-2 and RGS-3, which in turn downregulate Galpha signaling and behavioral sensitivity.	Quinine	46-53	cGMP-dependent protein kinase;cGMP-dependent protein kinase egl-4	Caenorhabditis elegans	32-37
22632934-2	2012	Herein we demonstrate the use of click chemistry to rapidly generate bivalent quinine dimers, containing an intervening triazole ring, as potential inhibitors of P-gp mediated efflux.	Quinine	78-85	phosphoglycolate phosphatase	Homo sapiens	162-166
22794107-5	2012	Although the feeding preference varied considerably among different strains and individuals, statistical analysis using large numbers of transformants indicated that transformants expressing T2R4 showed a small but significant increase in the preference for denatonium and quinine, the T2R4 ligands, as compared to the control flies, whereas transformants expressing T2R38 did not.	Quinine	273-280	taste 2 receptor member 4	Homo sapiens	191-195
22794107-5	2012	Although the feeding preference varied considerably among different strains and individuals, statistical analysis using large numbers of transformants indicated that transformants expressing T2R4 showed a small but significant increase in the preference for denatonium and quinine, the T2R4 ligands, as compared to the control flies, whereas transformants expressing T2R38 did not.	Quinine	273-280	taste 2 receptor member 38	Homo sapiens	367-372
27366135-6	2012	Aliquots of the extract were tested for their ability to inhibit the metabolism of the human CYP3A4 substrate quinine, using an in vitro liver microsomal technique.	Quinine	110-117	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	93-99
27366135-8	2012	Formation of quinine"s metabolite 3-hydroxyquinine, generated by the CYP3A4-mediated reaction was measured by a HPLC method.	Quinine	13-20	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	69-75
21789545-8	2012	TREK-1 inhibitor quinine inhibited the proliferation of astrocytes exposed to hypoxia condition.	Quinine	17-24	potassium two pore domain channel subfamily K member 2	Rattus norvegicus	0-6
21410689-10	2011	Methoctramine and quinine abolished BNP-induced relaxant activity.	Quinine	18-25	natriuretic peptide B	Homo sapiens	36-39
21154358-12	2010	The most commonly used quinine dosage was 300 mg/day (range 200 to 500 mg).Compared to placebo, quinine significantly reduced cramp number over two weeks by 28%, cramp intensity by 10%, and cramp days by 20%.	Quinine	96-103	cathelicidin antimicrobial peptide	Homo sapiens	126-131
21154358-12	2010	The most commonly used quinine dosage was 300 mg/day (range 200 to 500 mg).Compared to placebo, quinine significantly reduced cramp number over two weeks by 28%, cramp intensity by 10%, and cramp days by 20%.	Quinine	96-103	cathelicidin antimicrobial peptide	Homo sapiens	162-167
21154358-12	2010	The most commonly used quinine dosage was 300 mg/day (range 200 to 500 mg).Compared to placebo, quinine significantly reduced cramp number over two weeks by 28%, cramp intensity by 10%, and cramp days by 20%.	Quinine	96-103	cathelicidin antimicrobial peptide	Homo sapiens	162-167
21154358-17	2010	AUTHORS" CONCLUSIONS: There is moderate quality evidence that quinine significantly reduces cramp frequency, intensity and cramp days in dosages between 200 and 500 mg/day.	Quinine	62-69	cathelicidin antimicrobial peptide	Homo sapiens	92-97
21154358-17	2010	AUTHORS" CONCLUSIONS: There is moderate quality evidence that quinine significantly reduces cramp frequency, intensity and cramp days in dosages between 200 and 500 mg/day.	Quinine	62-69	cathelicidin antimicrobial peptide	Homo sapiens	123-128
20685138-6	2010	Quinine injection (35 pmol) into the EC of seizing animals decreased the amplitude and frequency of the discharge trains in the EC and CA1 regions, which were completely blocked after 34 min.	Quinine	0-7	carbonic anhydrase 1	Rattus norvegicus	135-138
20045733-7	2010	The purified rRBP elicited bitterness reduction against quinine and caffeine, although it largely lost its riboflavin-binding ability.	Quinine	56-63	retinol binding protein 4	Rattus norvegicus	13-17
20054526-5	2010	METHODS: Fourteen CML patients were phenotyped for in vivo CYP3A activity using quinine as a probe drug.	Quinine	80-87	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	59-64
20145204-3	2010	T1r3 knockout and wild-type mice were tested in behavioral preference assays for long-term voluntary intake of a broad concentration range of ethanol, sucrose, and quinine.	Quinine	164-171	taste receptor, type 1, member 3	Mus musculus	0-4
20054526-6	2010	The plasma concentration ratio of quinine and its CYP3A metabolite was used for assessing CYP3A activity.	Quinine	34-41	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	90-95
20054526-8	2010	RESULTS: Patients that achieved complete molecular response showed significantly (Mann-Whitney U-test, p=0.013) higher in vivo CYP3A activity (median quinine metabolic ratio = 10.1) than patients achieving partial molecular response (median = 15.9).	Quinine	150-157	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	127-132
20072781-8	2010	In contrast, mice lacking the alpha7 nAChR receptor subunit consumed significantly less ethanol than wild-type mice but consumed comparable amounts of water, saccharin, and quinine.	Quinine	173-180	cholinergic receptor, nicotinic, alpha polypeptide 7	Mus musculus	30-36
19353999-6	2009	Aliquots of the extract were tested for their ability to inhibit the metabolism of the human CYP3A4 probe quinine, using an in vitro liver microsomal technique.	Quinine	106-113	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	93-99
20218915-1	2009	The authors" laboratory has reported potent block of Pannexin1 (Panx1) currents by the antimalarial quinine derivative mefloquine.	Quinine	100-107	Pannexin 1	Rattus norvegicus	53-62
20218915-1	2009	The authors" laboratory has reported potent block of Pannexin1 (Panx1) currents by the antimalarial quinine derivative mefloquine.	Quinine	100-107	Pannexin 1	Rattus norvegicus	64-69
19765987-8	2009	Gr33a mutant flies were impaired in avoiding all nonvolatile repellents tested, ranging from quinine to denatonium, lobeline, and caffeine.	Quinine	93-100	Gustatory receptor 33a	Drosophila melanogaster	0-5
19747932-4	2009	In the present study, rats were used to examine the possible changes on the sleep-wake states after intracerebroventricular administration of several doses of quinine, a selective blocker of gap junctions formed by connexin36.	Quinine	159-166	gap junction protein, delta 2	Rattus norvegicus	215-225
19164511-3	2009	Here, rats and mice were used to determine whether nicotine activates peripheral and central taste pathways via TRPM5-dependent mechanisms, which are essential for responses to other bitter tastants such as quinine, and/or via nicotinic acetylcholine receptors (nAChRs).	Quinine	207-214	transient receptor potential cation channel, subfamily M, member 5	Mus musculus	112-117
19353999-8	2009	Formation of quinine"s metabolite 3-hydroxyquinine, generated by the CYP3A4-mediated reaction, was measured by HPLC.	Quinine	13-20	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	69-75
18945821-2	2009	In this work, rationally designed second-generation P-gp inhibitors are disclosed, based on dimerized versions of the substrates quinine and quinidine.	Quinine	129-136	ATP binding cassette subfamily B member 1	Homo sapiens	52-56
19260037-5	2009	A previous study of patients with "quinine-associated TTP/HUS" found that ADAMTS13 activities were not abnormal in 12/12 patients.	Quinine	35-42	ADAM metallopeptidase with thrombospondin type 1 motif 13	Homo sapiens	74-82
18945821-0	2009	Inhibition of P-glycoprotein-mediated paclitaxel resistance by reversibly linked quinine homodimers.	Quinine	81-88	ATP binding cassette subfamily B member 1	Homo sapiens	14-28
18288093-8	2008	We find that, similar to B6 mice, the D2.B6-Mop2-P1 congenic mice exhibit a strong preference for morphine over quinine, whereas D2.B6-Mop2-D1 congenic mice avoid morphine (similar to D2 mice).	Quinine	112-119	morphine preference 2	Mus musculus	44-48
18973419-6	2008	Because many antimalarial agents are effluxed by P-gp (mefloquine, quinine), it was important to determine whether CF1 mice can develop cerebral malaria to predict drug toxicity during cerebral malaria.	Quinine	67-74	phosphoglycolate phosphatase	Mus musculus	49-53
18300941-1	2008	OBJECTIVES: To study the potential endogenous marker of CYP3A activity, 4beta-hydroxycholesterol, and its relation to sex and the CYP3A5 geno/haplotypes and compare with CYP3A4/5 catalyzed 3-hydroxylation of quinine in the three major races.	Quinine	208-215	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	56-61
18300941-8	2008	The quinine/3-hydroxyquinine metabolic ratio was significantly different in all three populations with the highest CYP3A activity in Koreans and the lowest in Tanzanians.	Quinine	4-11	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	115-120
18300941-0	2008	4Beta-hydroxycholesterol is a new endogenous CYP3A marker: relationship to CYP3A5 genotype, quinine 3-hydroxylation and sex in Koreans, Swedes and Tanzanians.	Quinine	92-99	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	45-50
18300941-12	2008	Both 4beta-hydroxycholesterol and quinine/3-hydroxyquinine metabolic ratio showed a higher CYP3A activity in women than in men.	Quinine	34-41	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	91-96
18055813-9	2007	RESULTS: Junctional currents between lens epithelial cells exhibited a developmentally regulated sensitivity to quinine, a drug that blocks Cx50 gap junctions, but not Cx43 or Cx46.	Quinine	112-119	gap junction protein, alpha 8	Mus musculus	140-144
17376151-4	2008	In contrast, avoidance of quinine solutions was less in Gnat3 or Trpm5 knockout mice than in wild-type mice, whereas Tas1r3 null mice were not different from wild type in their response to quinine solutions.	Quinine	26-33	guanine nucleotide binding protein, alpha transducing 3	Mus musculus	56-61
17846099-2	2008	RBP elicited broadly tuned inhibition of various bitter substances including quinine-HCl, naringin, theobromine, caffeine, glycyl-L-phenylalanine (Gly-Phe), and denatonium benzoate, whereas several other proteins, such as ovalbumin (OVA) and beta-lactoglobulin, were ineffective in reducing bitterness of these same compounds.	Quinine	77-88	riboflavin binding protein	Gallus gallus	0-3
17846099-3	2008	Both the bitter tastes of quinine and caffeine were reduced following an oral prerinse with RBP.	Quinine	26-33	riboflavin binding protein	Gallus gallus	92-95
17846099-4	2008	It was found that RBP binds to quinine but not to caffeine, theobromine, naringin, and Gly-Phe.	Quinine	31-38	riboflavin binding protein	Gallus gallus	18-21
17846099-5	2008	However, the binding of RBP to quinine was probably not responsible for the bitter inhibition because OVA bound to quinine as well as RBP.	Quinine	31-38	riboflavin binding protein	Gallus gallus	24-27
17644186-1	2007	Quinone oxidoreductase (NQO1) plays a key role in the cellular antioxidant defense by detoxifying quinine derivatives.	Quinine	98-105	NAD(P)H quinone dehydrogenase 1	Homo sapiens	24-28
16683252-5	2006	The GAT1(-/-) mice showed decreased ethanol aversion and ethanol reward, and insensitivity to both the sedative/hypnotic and the motor stimulant effects of ethanol, along with increased avoidance of quinine preference and consumption.	Quinine	199-206	solute carrier family 6 (neurotransmitter transporter, GABA), member 1	Mus musculus	4-8
17644186-1	2007	Quinone oxidoreductase (NQO1) plays a key role in the cellular antioxidant defense by detoxifying quinine derivatives.	Quinine	98-105	crystallin zeta	Homo sapiens	0-22
16906018-13	2006	The CYP3A4 catalyzed hydroxylation of quinine (two low CYP3A5 expression alleles) was lower in Tanzanians than in Swedes.	Quinine	38-45	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	55-61
16807400-9	2006	Ammonium chloride-induced intracellular acidification significantly stimulated the hMATE2-K-dependent transport of organic cations such as TEA, MPP, procainamide, metformin, N1-methylnicotinamide, creatinine, guanidine, quinidine, quinine, thiamine, and verapamil.	Quinine	231-238	solute carrier family 47 member 2	Homo sapiens	83-89
17200836-0	2007	Inhibition of CYP3A4 and CYP3A5 catalyzed metabolism of alprazolam and quinine by ketoconazole as racemate and four different enantiomers.	Quinine	71-78	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	14-20
17200836-0	2007	Inhibition of CYP3A4 and CYP3A5 catalyzed metabolism of alprazolam and quinine by ketoconazole as racemate and four different enantiomers.	Quinine	71-78	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	25-31
17200836-7	2007	RESULTS: Quinine 3-hydroxylation was catalyzed to a similar extent by CYP3A4 and CYP3A5.	Quinine	9-16	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	70-76
17200836-7	2007	RESULTS: Quinine 3-hydroxylation was catalyzed to a similar extent by CYP3A4 and CYP3A5.	Quinine	9-16	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	81-87
17200836-10	2007	Quinine metabolism catalyzed by HLM, CYP3A4 and CYP3A5 was potently inhibited by the trans-enantiomer KTZ 2S,4S, with IC(50) value of 0.16 microM for HLM, 0.04 microM for CYP3A4 and 0.11 microM for CYP3A5.	Quinine	0-7	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	37-43
17200836-10	2007	Quinine metabolism catalyzed by HLM, CYP3A4 and CYP3A5 was potently inhibited by the trans-enantiomer KTZ 2S,4S, with IC(50) value of 0.16 microM for HLM, 0.04 microM for CYP3A4 and 0.11 microM for CYP3A5.	Quinine	0-7	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	48-54
17200836-10	2007	Quinine metabolism catalyzed by HLM, CYP3A4 and CYP3A5 was potently inhibited by the trans-enantiomer KTZ 2S,4S, with IC(50) value of 0.16 microM for HLM, 0.04 microM for CYP3A4 and 0.11 microM for CYP3A5.	Quinine	0-7	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	171-177
17200836-10	2007	Quinine metabolism catalyzed by HLM, CYP3A4 and CYP3A5 was potently inhibited by the trans-enantiomer KTZ 2S,4S, with IC(50) value of 0.16 microM for HLM, 0.04 microM for CYP3A4 and 0.11 microM for CYP3A5.	Quinine	0-7	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	198-204
17200836-13	2007	CONCLUSIONS: Alprazolam and quinine metabolism is catalyzed by both CYP3A4 and CYP3A5.	Quinine	28-35	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	68-74
17200836-13	2007	CONCLUSIONS: Alprazolam and quinine metabolism is catalyzed by both CYP3A4 and CYP3A5.	Quinine	28-35	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	79-85
16846720-8	2006	Transport of quinine in the secretory direction exceeded that in the absorptive direction and was saturable, suggesting quinine being a Pgp substrate.	Quinine	13-20	phosphoglycolate phosphatase	Homo sapiens	136-139
16846720-8	2006	Transport of quinine in the secretory direction exceeded that in the absorptive direction and was saturable, suggesting quinine being a Pgp substrate.	Quinine	120-127	phosphoglycolate phosphatase	Homo sapiens	136-139
16906018-0	2006	CYP3A5 genotype has significant effect on quinine 3-hydroxylation in Tanzanians, who have lower total CYP3A activity than a Swedish population.	Quinine	42-49	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	0-6
16906018-1	2006	OBJECTIVES: To study the correlation between CYP3A5 genotype and quinine 3-hydroxylation in black Tanzanian and Swedish Caucasians as well as to investigate the interethnic differences in CYP3A activity between the two populations.	Quinine	65-72	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	45-51
16906018-8	2006	The mean+/-SD quinine metabolic ratio (10.7+/-3.9) in Tanzanians homozygous for low CYP3A5 expression gene was significantly higher than the corresponding mean metabolic ratio in participants heterozygous (9.5+/-3.3; P=0.02) or homozygous (8.1+/-3.1; P=0.002) for high expression CYP3A5 alleles, respectively.	Quinine	14-21	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	84-90
16906018-10	2006	Tanzanians homozygous for low CYP3A5 expression gene (i.e. only CYP3A4 is expressed) had significantly (P&lt;0.0001) higher quinine metabolic ratio (10.7+/-3.9) than corresponding Swedes (7.7+/-3.1).	Quinine	124-131	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	30-36
16906018-12	2006	A significant association is noted between CYP3A5 genotype and quinine 3-hydroxylation in Tanzanians, indicating a significant contribution of CYP3A5 to total 3A activity.	Quinine	63-70	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	43-49
16906018-12	2006	A significant association is noted between CYP3A5 genotype and quinine 3-hydroxylation in Tanzanians, indicating a significant contribution of CYP3A5 to total 3A activity.	Quinine	63-70	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	143-149
16683252-6	2006	GAT1(+/-) mice showed significantly increased consumption of ethanol and saccharin, however, enhanced the rewarding and preference effect of ethanol, increased avoidance of quinine, and higher sensitivity to the motor stimulant effect of ethanol.	Quinine	173-180	solute carrier family 6 (neurotransmitter transporter, GABA), member 1	Mus musculus	0-4
16135743-3	2005	Although these findings confirm an essential role for PLCbeta2 in taste responsiveness to sucrose and to low- to midrange concentrations of quinine and denatonium in mice as previously reported, they importantly suggest that higher concentrations of the latter two compounds, which are bitter to humans, can engage a PLCbeta2-independent taste transduction pathway.	Quinine	140-147	phospholipase C beta 2	Homo sapiens	54-62
16171783-0	2005	Phenotype-genotype variability in the human CYP3A locus as assessed by the probe drug quinine and analyses of variant CYP3A4 alleles.	Quinine	86-93	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	44-49
16171783-3	2005	Tanzanian (n=143) healthy volunteers were phenotyped using quinine as a CYP3A probe and the results were used for association studies with CYP3A4 genotypes.	Quinine	59-66	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	72-77
16421215-3	2005	Regulation of cellular volume, as measured by flow cytometry, was inhibited when spermatozoa were exposed to quinine (QUI; 0.3 mM), 4-aminopyridine (4AP; 4 mM) and clofilium (CLO; 10 microM) which suggests the involvement of voltage-gated K+ channels Kv1.4, Kv1.5 and Kv1.7, acid-sensitive channel TASK2 and the beta-subunit minK (IsK) in regulatory volume decrease (RVD).	Quinine	118-121	potassium voltage-gated channel subfamily A member 7	Homo sapiens	268-273
16099839-8	2005	Prototype OCT inhibitors, including cimetidine, and type II cations (e.g., quinidine, quinine, verapamil, and rhodamine123) are also PMAT inhibitors.	Quinine	86-93	solute carrier family 29 member 4	Homo sapiens	133-137
16420686-2	2006	For instance, pfmdr1 gene amplification has been associated with resistance to quinine derivatives and several genes involved in anti-oxidant defence may play an important role in resistance to antimalarial drugs, although their potential involvement has been overlooked.	Quinine	79-86	multidrug resistance protein 1	Plasmodium falciparum 3D7	14-20
16421215-3	2005	Regulation of cellular volume, as measured by flow cytometry, was inhibited when spermatozoa were exposed to quinine (QUI; 0.3 mM), 4-aminopyridine (4AP; 4 mM) and clofilium (CLO; 10 microM) which suggests the involvement of voltage-gated K+ channels Kv1.4, Kv1.5 and Kv1.7, acid-sensitive channel TASK2 and the beta-subunit minK (IsK) in regulatory volume decrease (RVD).	Quinine	109-116	potassium voltage-gated channel subfamily A member 5	Homo sapiens	258-263
16421215-3	2005	Regulation of cellular volume, as measured by flow cytometry, was inhibited when spermatozoa were exposed to quinine (QUI; 0.3 mM), 4-aminopyridine (4AP; 4 mM) and clofilium (CLO; 10 microM) which suggests the involvement of voltage-gated K+ channels Kv1.4, Kv1.5 and Kv1.7, acid-sensitive channel TASK2 and the beta-subunit minK (IsK) in regulatory volume decrease (RVD).	Quinine	109-116	potassium voltage-gated channel subfamily A member 7	Homo sapiens	268-273
16421215-3	2005	Regulation of cellular volume, as measured by flow cytometry, was inhibited when spermatozoa were exposed to quinine (QUI; 0.3 mM), 4-aminopyridine (4AP; 4 mM) and clofilium (CLO; 10 microM) which suggests the involvement of voltage-gated K+ channels Kv1.4, Kv1.5 and Kv1.7, acid-sensitive channel TASK2 and the beta-subunit minK (IsK) in regulatory volume decrease (RVD).	Quinine	118-121	potassium voltage-gated channel subfamily A member 5	Homo sapiens	258-263
16190928-0	2005	Quinine, a blocker of neuronal cx36 channels, suppresses seizure activity in rat neocortex in vivo.	Quinine	0-7	gap junction protein, delta 2	Rattus norvegicus	31-35
16190928-3	2005	RESULTS: The blockade of Cx36 channels by quinine before the induction of epileptiform activity slightly reduced the epileptogenesis.	Quinine	42-49	gap junction protein, delta 2	Rattus norvegicus	25-29
15926192-1	2005	In order to find what types of hepatic microsomal cytochrome P450 (CYP) isozymes are involved in the metabolism of DA-8159 and in the formation of DA-8164 in rats, enzyme inducers, such as dexamethasone, phenobarbital, 3-methylcholanthrene and isoniazid, and enzyme inhibitors, such as troleandomycin and quinine, were pretreated in rats.	Quinine	305-312	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	50-65
15926192-1	2005	In order to find what types of hepatic microsomal cytochrome P450 (CYP) isozymes are involved in the metabolism of DA-8159 and in the formation of DA-8164 in rats, enzyme inducers, such as dexamethasone, phenobarbital, 3-methylcholanthrene and isoniazid, and enzyme inhibitors, such as troleandomycin and quinine, were pretreated in rats.	Quinine	305-312	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	67-70
15896247-2	2005	The major metabolite of quinine is 3-hydroxyquinine formed by cytochrome P450 3A4 (CYP3A4).	Quinine	24-31	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	83-89
15896247-3	2005	Ketoconazole, a potent inhibitor of CYP3A4, is known to markedly increase plasma concentrations of various co-administered drugs including quinine.	Quinine	139-146	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	36-42
15494300-9	2004	However, another first-generation blocker, quinine, was used in MDS and may specifically benefit MDS patients overexpressing Pgp.	Quinine	43-50	ATP binding cassette subfamily B member 1	Homo sapiens	125-128
15508023-8	2005	When quinine was eliminated from the control bottle, morphine preference in B6.D2-Mop2 mice was decreased significantly relative to B6 and D2.B6-Mop2 mice.	Quinine	5-12	morphine preference 2	Mus musculus	82-86
15508023-8	2005	When quinine was eliminated from the control bottle, morphine preference in B6.D2-Mop2 mice was decreased significantly relative to B6 and D2.B6-Mop2 mice.	Quinine	5-12	defensin beta 2	Mus musculus	132-141
15508023-8	2005	When quinine was eliminated from the control bottle, morphine preference in B6.D2-Mop2 mice was decreased significantly relative to B6 and D2.B6-Mop2 mice.	Quinine	5-12	morphine preference 2	Mus musculus	145-149
15791644-8	2005	Furthermore, tracer coupling between OFF-alpha-ganglion cells could be inhibited by quinine, a gap junctional blocker with a slight preference for gap junctions formed by Cx36.	Quinine	84-91	gap junction protein, delta 2	Mus musculus	171-175
12738668-0	2003	Drug-induced thrombocytopenia: localization of the binding site of GPIX-specific quinine-dependent antibodies.	Quinine	81-88	glycoprotein 9 (platelet)	Mus musculus	67-71
15083252-7	2004	In agreement with this finding, the differences between WT and CB1-KO mice faded away when the palatability of sucrose was devaluated by adding quinine, but not when a non-caloric sweetener, saccharin, was available.	Quinine	144-151	cannabinoid receptor 1 (brain)	Mus musculus	63-66
15120584-5	2004	Administration of CYP2D inhibitor, quinine, jointly with TIQ lowered the levels of TH and DA in that structure, but slightly increased DAT binding.	Quinine	35-42	solute carrier family 6 member 3	Rattus norvegicus	135-138
14738594-7	2003	Secondly, we studied the inhibition of CYP2A6 with clinically used drugs of quinoline compounds, such as norfloxacin as an antibacterial agent, quinidine as an antiarrhythmic agent, quinine and chloroquine as antimalaria agents and rebamipide as an anti-ulcer agent.	Quinine	182-189	cytochrome P450 2A13	Bos taurus	39-45
14738594-10	2003	The IC50 value of quinine was 160 microM with weak inhibition, suggesting that quinine, at a high dose, influences the metabolism of substrates for CYP2A6 by drug-drug interaction.	Quinine	18-25	cytochrome P450 2A13	Bos taurus	148-154
14738594-10	2003	The IC50 value of quinine was 160 microM with weak inhibition, suggesting that quinine, at a high dose, influences the metabolism of substrates for CYP2A6 by drug-drug interaction.	Quinine	79-86	cytochrome P450 2A13	Bos taurus	148-154
14738594-11	2003	These results also show that CYP2A6 discriminates the structure difference between the diastereoisomers quinidine and quinine.	Quinine	118-125	cytochrome P450 2A13	Bos taurus	29-35
12738668-5	2003	In our series of patients, GPIX was the most prevalent target of quinine-dependent antibodies.	Quinine	65-72	glycoprotein IX platelet	Homo sapiens	27-31
12738668-7	2003	The analysis of 6 patient sera with the chimeric cell lines provided evidence for localization of the anti-GPIX quinine-dependent antibody binding site to the C-ext region (amino acid [aa] 64-135) of human GPIX.	Quinine	112-119	glycoprotein 9 (platelet)	Mus musculus	107-111
12738668-7	2003	The analysis of 6 patient sera with the chimeric cell lines provided evidence for localization of the anti-GPIX quinine-dependent antibody binding site to the C-ext region (amino acid [aa] 64-135) of human GPIX.	Quinine	112-119	glycoprotein IX platelet	Homo sapiens	206-210
14979094-3	2003	Compared to microsomes incubated without quinine, where cholinesterase activity was inhibited to a mean 53% (chlorpyriphos) and 57% (aldicarb) of control, the introduction of P450 2D6 inhibitor quinine into microsomal incubation mixture reduced cholinesterase activity to 72% of control for chlorpyriphos and to 27% for aldicarb, suggesting that P450 2D6 is involved in the activation of chlorpyriphos but does not influence aldicarb toxicity on acetylcholinesterase.	Quinine	41-48	butyrylcholinesterase	Rattus norvegicus	56-70
12864851-9	2003	pfmdr1 transcript levels specifically increased 2.5-fold at 6 h in mefloquine-treated parasites and threefold in parasites treated with quinine for 30 min.	Quinine	136-143	multidrug resistance protein 1	Plasmodium falciparum 3D7	0-6
12754259-7	2003	Pharmacological analysis showed TRESK to be inhibited by previously reported K+ channel inhibitors Ba2+, propafenone, glyburide, lidocaine, quinine, quinidine, and triethanolamine.	Quinine	140-147	potassium two pore domain channel subfamily K member 18	Homo sapiens	32-37
14979094-3	2003	Compared to microsomes incubated without quinine, where cholinesterase activity was inhibited to a mean 53% (chlorpyriphos) and 57% (aldicarb) of control, the introduction of P450 2D6 inhibitor quinine into microsomal incubation mixture reduced cholinesterase activity to 72% of control for chlorpyriphos and to 27% for aldicarb, suggesting that P450 2D6 is involved in the activation of chlorpyriphos but does not influence aldicarb toxicity on acetylcholinesterase.	Quinine	194-201	butyrylcholinesterase	Rattus norvegicus	56-70
12695533-4	2003	Block of HERG by quinidine (and its isomer quinine) was enhanced by progressive membrane depolarization and accompanied by a negative shift in the voltage dependence of channel activation.	Quinine	43-50	potassium voltage-gated channel subfamily H member 2	Homo sapiens	9-13
12626647-3	2003	The beta 2 null mutants showed decreased consumption of saccharin and quinine, but not ethanol.	Quinine	70-77	hemoglobin, beta adult minor chain	Mus musculus	4-10
12743670-0	2003	Quinine 3-hydroxylation as a biomarker reaction for the activity of CYP3A4 in man.	Quinine	0-7	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	68-74
12743670-1	2003	OBJECTIVE: To investigate the usefulness of the 3-hydroxylation of quinine as a biomarker reaction for the activity of CYP3A4 in man and to study the interindividual variation in the metabolic ratio (MR), i.e. quinine/3-hydroxyquinine.	Quinine	67-74	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	119-125
12743670-11	2003	CONCLUSIONS: The MR of quinine in plasma or urine may serve as a stable measure of the activity of CYP3A4 in man.	Quinine	23-30	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	99-105
12743670-12	2003	These results together with in vitro data show that quinine is also a specific CYP3A4 probe.	Quinine	52-59	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	79-85
12695533-6	2003	Mutations of Y652 eliminated (Y652F) or reversed (Y652A) the voltage dependence of HERG channel block by quinidine and quinine.	Quinine	119-126	potassium voltage-gated channel subfamily H member 2	Homo sapiens	83-87
12433805-0	2002	Enzyme kinetics for the formation of 3-hydroxyquinine and three new metabolites of quinine in vitro; 3-hydroxylation by CYP3A4 is indeed the major metabolic pathway.	Quinine	46-53	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	120-126
12393510-0	2003	A site involving the "hybrid" and PSI homology domains of GPIIIa (beta 3-integrin subunit) is a common target for antibodies associated with quinine-induced immune thrombocytopenia.	Quinine	141-148	integrin subunit beta 3	Homo sapiens	58-64
12393510-3	2003	We studied a group of quinine-dependent antibodies that react with human glycoprotein IIIa (GPIIIa; beta3-integrin subunit) but fail to recognize rat GPIIIa, despite close homology between the 2 proteins.	Quinine	22-29	integrin subunit beta 3	Homo sapiens	92-98
12393510-4	2003	By characterizing reactions of these antibodies with human/rat GPIIIa chimeras and selected GPIIIa mutants, we found that each of 3 quinine-dependent antibodies requires a 17-amino acid sequence in the newly recognized "hybrid" and PSI homology domains of GPIIIa for drug-dependent binding.	Quinine	132-139	integrin subunit beta 3	Homo sapiens	63-69
12393510-4	2003	By characterizing reactions of these antibodies with human/rat GPIIIa chimeras and selected GPIIIa mutants, we found that each of 3 quinine-dependent antibodies requires a 17-amino acid sequence in the newly recognized "hybrid" and PSI homology domains of GPIIIa for drug-dependent binding.	Quinine	132-139	integrin subunit beta 3	Homo sapiens	92-98
12393510-4	2003	By characterizing reactions of these antibodies with human/rat GPIIIa chimeras and selected GPIIIa mutants, we found that each of 3 quinine-dependent antibodies requires a 17-amino acid sequence in the newly recognized "hybrid" and PSI homology domains of GPIIIa for drug-dependent binding.	Quinine	132-139	integrin subunit beta 3	Homo sapiens	92-98
12393510-7	2003	The findings suggest this region of GPIIIa may be a favored target for quinine-dependent antibodies and may provide a basis for further studies to elucidate the molecular basis of glycoprotein-drug-antibody interaction.	Quinine	71-78	integrin subunit beta 3	Homo sapiens	36-42
12502361-6	2003	MD studies on the binding mode of sparteine, quinidine, and quinine in CYP2D2 and CYP2D6 furthermore concurred well with experimentally determined IC(50) values and metabolic profiles.	Quinine	60-67	cytochrome P450, family 2, subfamily d, polypeptide 4	Rattus norvegicus	82-88
12433805-11	2002	There was a significant correlation between the formation rates of quinine metabolites and activities of the CYP3A4 selected marker probes.	Quinine	67-74	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	109-115
12433805-12	2002	This in vitro study demonstrates that 3-hydroxyquinine is the principal metabolite of quinine and CYP3A4 is the major enzyme involved in this metabolic pathway.	Quinine	47-54	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	98-104
12151796-8	2002	There was a tendency for quinine stimulation, a bitter stimulus that lowers cAMP, to reduce CREB phosphorylation.	Quinine	25-32	cAMP responsive element binding protein 1	Rattus norvegicus	92-96
12438515-5	2002	In proximal tubules, procainamide, quinine, cyanine(863), choline, and guanidine in concentrations that inhibit rOCT1/2-mediated TEA or amantadine uptake in Xenopus oocytes exhibited no effect on amantadine uptake.	Quinine	35-42	solute carrier family 22 member 1	Rattus norvegicus	112-117
12468583-4	2002	Patch-clamp of cerebral smooth muscle cells pairs from SHR versus WKY showed a significantly steeper voltage dependence of deactivation and partial block of junctional currents by quinine and by a peptide that interferes with docking of Cx45, consistent with dominance of functional Cx45 channels in SHR.	Quinine	180-187	gap junction protein, gamma 1	Rattus norvegicus	237-241
12468583-4	2002	Patch-clamp of cerebral smooth muscle cells pairs from SHR versus WKY showed a significantly steeper voltage dependence of deactivation and partial block of junctional currents by quinine and by a peptide that interferes with docking of Cx45, consistent with dominance of functional Cx45 channels in SHR.	Quinine	180-187	gap junction protein, gamma 1	Rattus norvegicus	283-287
12393164-4	2002	The cinchona alkaloid quinine also effectively blocked the inward current, and in addition, enhanced significantly the Cx38 hemichannel currents in a dose-dependent fashion; the Hill coefficient of 1.9 suggests that the binding of at least two molecules of quinine is required to produce the effect.	Quinine	22-29	connexin 38 S homeolog	Xenopus laevis	119-123
12393164-4	2002	The cinchona alkaloid quinine also effectively blocked the inward current, and in addition, enhanced significantly the Cx38 hemichannel currents in a dose-dependent fashion; the Hill coefficient of 1.9 suggests that the binding of at least two molecules of quinine is required to produce the effect.	Quinine	257-264	connexin 38 S homeolog	Xenopus laevis	119-123
12497978-11	2002	The present data confirm previous studies showing that quinine depresses plasma glucose through stimulation of insulin secretion.	Quinine	55-62	insulin	Homo sapiens	111-118
12010763-0	2002	Quinine and citric acid elicit distinctive Fos-like immunoreactivity in the rat nucleus of the solitary tract.	Quinine	0-7	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	43-46
12068242-15	2002	DAT-KO mice also demonstrated altered taste preference for saccharin and quinine.	Quinine	73-80	solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	Mus musculus	0-3
11765139-0	2001	Differential inhibition of human CYP1A1 and CYP1A2 by quinidine and quinine.	Quinine	68-75	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	33-39
11883641-5	2002	whereas digoxin, quinine, and rifampicin preferentially inhibited Oatp2 at low concentrations.	Quinine	17-24	solute carrier organic anion transporter family, member 1a4	Rattus norvegicus	66-71
12023534-0	2002	4-Hydroxylation of debrisoquine by human CYP1A1 and its inhibition by quinidine and quinine.	Quinine	84-91	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	41-47
12023534-5	2002	Additionally and surprisingly, this reaction was also inhibited by quinidine and quinine, with respective IC(50) values of 1.38 +/- 0.10 and 3.31 +/- 0.14 microM, compared with those for CYP2D6 debrisoquine 4-hydroxylase of 0.018 +/- 0.05 and 3.75 +/- 2.07 microM, respectively.	Quinine	81-88	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	187-193
12023534-5	2002	Additionally and surprisingly, this reaction was also inhibited by quinidine and quinine, with respective IC(50) values of 1.38 +/- 0.10 and 3.31 +/- 0.14 microM, compared with those for CYP2D6 debrisoquine 4-hydroxylase of 0.018 +/- 0.05 and 3.75 +/- 2.07 microM, respectively.	Quinine	81-88	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	194-220
11704264-1	2001	We have reported that a diazepam binding inhibitor (DBI)-like peptide is released by the aversive quinine stimuli "Chem.	Quinine	98-105	diazepam binding inhibitor	Mus musculus	24-50
11704264-1	2001	We have reported that a diazepam binding inhibitor (DBI)-like peptide is released by the aversive quinine stimuli "Chem.	Quinine	98-105	diazepam binding inhibitor	Mus musculus	52-55
11704264-4	2001	DBI suppressed the intake of 5% sucrose, water and 0.9 mM quinine-HCl and the preference for 0.05% saccharin.	Quinine	58-69	diazepam binding inhibitor	Mus musculus	0-3
11765139-0	2001	Differential inhibition of human CYP1A1 and CYP1A2 by quinidine and quinine.	Quinine	68-75	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	44-50
11765139-2	2001	The inhibition of recombinant CYP1A1 and CYP1A2 activity by quinidine and quinine was evluated using ethoxyresorutin O-deethylation, phenacetin O-deethylation and propranolol desisopropylation as probe catalytic pathways.	Quinine	74-81	cytochrome P450, family 1, subfamily a, polypeptide 1	Rattus norvegicus	30-36
11765139-2	2001	The inhibition of recombinant CYP1A1 and CYP1A2 activity by quinidine and quinine was evluated using ethoxyresorutin O-deethylation, phenacetin O-deethylation and propranolol desisopropylation as probe catalytic pathways.	Quinine	74-81	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	41-47
11765139-4	2001	With substrate concentrations near the Km of catalysis, both quinidine and quinine potently inhibited CYP1A1 activity with [I](0.5) approximately 1-3 microM, whereas in contrast, there was little inhibition of CYP1A2 activity.	Quinine	75-82	cytochrome P450, family 1, subfamily a, polypeptide 1	Rattus norvegicus	102-108
11765139-4	2001	With substrate concentrations near the Km of catalysis, both quinidine and quinine potently inhibited CYP1A1 activity with [I](0.5) approximately 1-3 microM, whereas in contrast, there was little inhibition of CYP1A2 activity.	Quinine	75-82	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	210-216
11279194-5	2001	The activity of NHE7 was also found to be relatively insensitive to inhibition by amiloride but could be antagonized by the analogue benzamil and the unrelated compound quinine.	Quinine	169-176	solute carrier family 9 member A7	Homo sapiens	16-20
11737987-2	2001	METHODS: The effects of various flavonoids and furanocoumarin derivatives on CYP3A4 activity in two human liver microsomal samples was determined using quinine as a substrate.	Quinine	152-159	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	77-83
11737987-5	2001	RESULTS: The results showed that the inhibition of quinine 3-hydroxylation (CYP3A4 activity) by bergapten (67%), and quercetin (55%) was greater than naringenin (39%) and naringin (6%), at the same inhibitor concentration of 100 M. The results also demonstrated that the furan ring in the furanocoumarins enhanced the inhibitory effect on CYP3A4 activity.	Quinine	51-58	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	76-82
11737987-5	2001	RESULTS: The results showed that the inhibition of quinine 3-hydroxylation (CYP3A4 activity) by bergapten (67%), and quercetin (55%) was greater than naringenin (39%) and naringin (6%), at the same inhibitor concentration of 100 M. The results also demonstrated that the furan ring in the furanocoumarins enhanced the inhibitory effect on CYP3A4 activity.	Quinine	51-58	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	339-345
11502595-0	2001	Interaction of cations, anions, and weak base quinine with rat renal cation transporter rOCT2 compared with rOCT1.	Quinine	46-53	solute carrier family 22 member 2	Rattus norvegicus	88-93
11502595-8	2001	Inhibition experiments at different pH levels strongly suggest that the weak base quinine passively permeates the plasma membrane at physiological pH and inhibits rOCT2 from the intracellular side.	Quinine	82-89	solute carrier family 22 member 2	Rattus norvegicus	163-168
11114152-0	2000	Diazepam-binding inhibitor-like activity in rat cerebrospinal fluid after stimulation by an aversive quinine taste.	Quinine	101-108	diazepam binding inhibitor	Rattus norvegicus	0-26
11248242-4	2001	TASK-4 currents were efficiently blocked by barium (83% inhibition at 2 mM), only weakly inhibited by 1 mM concentrations of quinine, bupivacaine and lidocaine, but not blocked by tetraethylammonium, 4-aminopyridine and Cs(+).	Quinine	125-132	potassium two pore domain channel subfamily K member 17	Homo sapiens	0-6
11294244-5	2001	The BK channel was inhibited reversibly by external tetraethylammonium (TEA) ions, charybdotoxin, and quinine and was resistant to block by 4-aminopyridine and apamin.	Quinine	102-109	potassium calcium-activated channel subfamily M alpha 1	Rattus norvegicus	4-14
10806376-9	2000	The reaction was sensitive to inhibition by the CYP2D6-selective inhibitors quinidine, quinine, lobeline and norfluoxetine, whereas chemical inhibitors selective for other CYP isoforms failed to affect the reaction.	Quinine	87-94	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	48-54
10887187-7	2000	In a physiological K(+) gradient, TWIK-2 is half inhibited by 0.1 mm Ba(2+), quinine, and quinidine.	Quinine	77-84	potassium two pore domain channel subfamily K member 6	Homo sapiens	34-40
11042226-4	2000	Polarised transport of doxorubicin in the Caco-2 and the LLC-PK1:MDR1 cell lines could be inhibited by the P-gp inhibitors SDZ-PSC 833 (PSC 833), cyclosporin A (CsA), verapamil and quinine, but not by the inhibitors for the organic cation carrier systems cimetidine and tetraethylammonium (TEA).	Quinine	181-188	ATP binding cassette subfamily B member 1	Homo sapiens	107-111
10833427-4	2000	Growth rescue of Kir 6.1, Kir 6.2 and the above mutants can be inhibited by pharmacological agents (cesium ions, phentolamine and quinine) known to decrease channel activity by direct interaction with the pore forming subunit.	Quinine	130-137	potassium inwardly rectifying channel subfamily J member 8	Homo sapiens	17-24
10833427-4	2000	Growth rescue of Kir 6.1, Kir 6.2 and the above mutants can be inhibited by pharmacological agents (cesium ions, phentolamine and quinine) known to decrease channel activity by direct interaction with the pore forming subunit.	Quinine	130-137	potassium inwardly rectifying channel subfamily J member 11	Homo sapiens	26-33
10736425-7	2000	Moreover, using IAAQ, we showed that molar excesses of chloroquine, quinine, quinidine, and MK-571 inhibit the photoaffinity labeling of MRP.	Quinine	68-75	ATP binding cassette subfamily C member 3	Homo sapiens	137-140
10806376-9	2000	The reaction was sensitive to inhibition by the CYP2D6-selective inhibitors quinidine, quinine, lobeline and norfluoxetine, whereas chemical inhibitors selective for other CYP isoforms failed to affect the reaction.	Quinine	87-94	cytochrome P450 family 2 subfamily D member 6	Sus scrofa	48-51
10456490-1	1999	OBJECTIVE: As quinine is mainly metabolised by human liver CYP3A4 and grapefruit juice inhibits CYP3A4, the effect of grapefruit juice on the pharmacokinetics of quinine following a single oral dose of 600 mg quinine sulphate was investigated.	Quinine	14-21	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	59-65
10831384-1	2000	A multidrug-resistant strain of Plasmodium yoelii nigeriensis (MDR) showing a wide spectrum of resistance to chloroquine, amodiaquine, mepacrine, mefloquine, halofantrine, quinine, and quinidine was used in this study for in vivo evaluation of the blood schizontocidal activity of pyronaridine, a topoisomerase II inhibitor, in Swiss mice.	Quinine	172-179	malic enzyme complex, mitochondrial	Mus musculus	63-66
10449792-3	1999	We have monitored this activation with an in vitro assay to identify compounds that inhibited taste receptor activation of transducin by bitter tastants: AMP and chemically related compounds inhibited in vitro responses to several bitter compounds (e.g., denatonium, quinine, strychnine, and atropine).	Quinine	267-274	guanine nucleotide binding protein, alpha transducing 1	Mus musculus	123-133
10706865-6	2000	This finding not only confirms that the epitope of the rifampicin-dependent antibody is on GPIX but it is also identical to or located in close proximity to that of the quinine-dependent antibody and SZ1.	Quinine	169-176	glycoprotein IX platelet	Homo sapiens	91-95
10661723-0	1999	In vitro hepatic metabolism of a CYP3A-mediated drug, quinine, in Adelie penguins.	Quinine	54-61	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	33-38
10661723-2	1999	The activity of cytochromes P450 subfamily 3A (CYP3A) in Adelie penguin liver was studied by incubating penguin liver microsomes with a human CYP3A substrate, quinine, and results were compared with those from human liver microsomes.	Quinine	159-166	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	47-52
10661723-5	1999	3-Hydroxyquinine formation in penguin liver was inhibited by specific CYP3A inhibitors, midazolam and troleandomycin, but not by other CYP inhibitors, indicating that quinine metabolism to 3-hydroxyquinine in Adelie penguin liver is likely to be catalysed by a CYP isoform resembling human CYP3A.	Quinine	9-16	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	70-75
10661723-5	1999	3-Hydroxyquinine formation in penguin liver was inhibited by specific CYP3A inhibitors, midazolam and troleandomycin, but not by other CYP inhibitors, indicating that quinine metabolism to 3-hydroxyquinine in Adelie penguin liver is likely to be catalysed by a CYP isoform resembling human CYP3A.	Quinine	9-16	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	290-295
10421620-7	1999	The enzyme activity was significantly (p &lt;.01) and stereoselectively inhibited by CYP2D1 inhibitors quinine and quinidine (not by CYP2C or CYP3A inhibitors), and by anti-CYP2D6 peptide antiserum (not by anti-CYP2C, -CYP2B, or -CYP3A antibodies).	Quinine	103-110	cytochrome P450, family 2, subfamily d, polypeptide 1	Rattus norvegicus	85-91
10421620-7	1999	The enzyme activity was significantly (p &lt;.01) and stereoselectively inhibited by CYP2D1 inhibitors quinine and quinidine (not by CYP2C or CYP3A inhibitors), and by anti-CYP2D6 peptide antiserum (not by anti-CYP2C, -CYP2B, or -CYP3A antibodies).	Quinine	103-110	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	173-179
9746775-4	1998	From the pattern of monoclonal antibody (MoAb) inhibition and the reactions of antibody with Chinese hamster ovary (CHO) cells transfected with GPIX and GPIbbeta, we found that the patient"s antibody is specific for an epitope on GPIX close to, or identical with a site recognized by the MoAb SZ1 that is a common target for antibodies induced by quinine and quinidine, drugs structurally unrelated to ranitidine.	Quinine	347-354	glycoprotein IX platelet	Homo sapiens	144-148
10215651-8	1999	OCTN1-mediated [14C]TEA uptake was inhibited by various organic cations such as cimetidine, procainamide, pyrilamine, quinidine, quinine, and verapamil.	Quinine	129-136	solute carrier family 22 member 4	Homo sapiens	0-5
10024310-7	1999	Ang II (100 nmol/L), in the presence of the AT2 receptor blocker PD123,319, elicited an inhibition of neuronal K+ current that was abolished by quinine (50 micromol/L).	Quinine	144-151	angiotensinogen	Rattus norvegicus	0-6
10471068-11	1999	Furthermore, quinine markedly inhibited CYP2D2-mediated debrisoquine and metoprolol oxidation, while quinidine, its diastereoisomer, inhibited the reactions to a lesser extent.	Quinine	13-20	cytochrome P450, family 2, subfamily d, polypeptide 2	Rattus norvegicus	40-46
10075682-8	1999	Pharmacologically, TWIK-2 channels are distinct from TWIK-1 channels in their response to quinidine, quinine, and barium.	Quinine	101-108	potassium two pore domain channel subfamily K member 6	Homo sapiens	19-25
10075682-8	1999	Pharmacologically, TWIK-2 channels are distinct from TWIK-1 channels in their response to quinidine, quinine, and barium.	Quinine	101-108	potassium channel, two pore domain subfamily K, member 1 L homeolog	Xenopus laevis	53-59
10024310-6	1999	Biophysical examination of the quinine-sensitive neuronal K+ current demonstrated a macroscopic conductance with similar biophysical properties to those of Kv2.2 and Kv3.1b.	Quinine	31-38	potassium channel, voltage gated Shab related subfamily B, member 2 S homeolog	Xenopus laevis	156-161
10500778-0	1999	Quinine improves results of intensive chemotherapy (IC) in myelodysplastic syndromes (MDS) expressing P-glycoprotein (PGP).	Quinine	0-7	ATP binding cassette subfamily B member 1	Homo sapiens	102-116
10500778-0	1999	Quinine improves results of intensive chemotherapy (IC) in myelodysplastic syndromes (MDS) expressing P-glycoprotein (PGP).	Quinine	0-7	ATP binding cassette subfamily B member 1	Homo sapiens	118-121
10500778-7	1999	In PGP positive cases, 13 of the 25 (52%) patients who received quinine achieved CR, as compared to 3 of the 17 (18%) patients treated with chemotherapy alone (p = 0.02).	Quinine	64-71	ATP binding cassette subfamily B member 1	Homo sapiens	3-6
10500778-8	1999	In PGP negative cases, the CR rate was 35% and 49%, respectively in patients who received quinine or chemotherapy alone (difference not significant).	Quinine	90-97	ATP binding cassette subfamily B member 1	Homo sapiens	3-6
10500778-9	1999	In the 42 PGP positive patients, median Kaplan-Meier (KM) survival was 13 months in patients allocated to the quinine group, and 8 months in patients treated with chemotherapy alone (p = 0.01).	Quinine	110-117	ATP binding cassette subfamily B member 1	Homo sapiens	10-13
10500778-10	1999	In PGP negative patients, median KM survival was 14 months in patients allocated to the quinine group, and 14 months in patients treated with chemotherapy alone.	Quinine	88-95	ATP binding cassette subfamily B member 1	Homo sapiens	3-6
10500778-14	1999	In conclusion, results of this randomized study show that quinine increases the CR rate and survival in PGP positive MDS cases treated with IC.	Quinine	58-65	ATP binding cassette subfamily B member 1	Homo sapiens	104-107
10392310-4	1999	Among several specific CYP isozyme inhibitors including troleandomycin (TAO), diethyldithiocarbamate, furafylline and quinine, only TAO showed marked inhibition of FBPA formation.	Quinine	118-125	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	23-26
9734653-0	1998	Quinine improves the results of intensive chemotherapy in myelodysplastic syndromes expressing P glycoprotein: results of a randomized study.	Quinine	0-7	ATP binding cassette subfamily B member 1	Homo sapiens	95-109
9721180-9	1998	The human CYP2D6-specific inhibitor quinidine and the rat CYP2D1-specific inhibitor quinine were both shown to be inhibitors of bufuralol 1"-hydroxylase activity for dog liver microsomes, CYP2D15 WT2, and the CYP2D15 V1 variant with nearly equal potency.	Quinine	84-91	cytochrome P450, family 2, subfamily d, polypeptide 1	Rattus norvegicus	58-64
9721180-9	1998	The human CYP2D6-specific inhibitor quinidine and the rat CYP2D1-specific inhibitor quinine were both shown to be inhibitors of bufuralol 1"-hydroxylase activity for dog liver microsomes, CYP2D15 WT2, and the CYP2D15 V1 variant with nearly equal potency.	Quinine	84-91	cytochrome P450 2D15	Canis lupus familiaris	188-195
9721180-9	1998	The human CYP2D6-specific inhibitor quinidine and the rat CYP2D1-specific inhibitor quinine were both shown to be inhibitors of bufuralol 1"-hydroxylase activity for dog liver microsomes, CYP2D15 WT2, and the CYP2D15 V1 variant with nearly equal potency.	Quinine	84-91	cytochrome P450 2D15	Canis lupus familiaris	209-216
9721180-10	1998	Thus, the dog expresses a CYP2D ortholog possessing enzymatic activities similar to human CYP2D6, but is affected by the inhibitors quinine and quinidine in a manner closer to that of rat CYP2D1.	Quinine	132-139	cytochrome P450 2D15	Canis lupus familiaris	26-31
9734653-8	1998	In conclusion, the results of this randomized study show that quinine increases the CR rate and survival in PGP-positive MDS cases treated with intensive chemotherapy.	Quinine	62-69	ATP binding cassette subfamily B member 1	Homo sapiens	108-111
9256169-6	1997	The binding of [3H]GBR-12935 to CYP2D6 was decreased partially by substrates or inhibitors of CYP2D isoforms (quinine, quinidine, propranolol, bufuralol, imipramine, and desipramine).	Quinine	110-117	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	32-38
9399990-1	1997	The major metabolic pathway of quinine in the human has been shown to be 3-hydroxylation mediated mainly by human cytochrome P450 (CYP) 3A4.	Quinine	31-38	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	114-139
9399990-7	1997	Antisera raised against rat CYP3A2 strongly inhibited quinine 3-hydroxylation by about 96, 84 and 92% with mouse, rat and dog liver microsomes, respectively, but neither anti-rat 2C11 and 2E1 antisera did so with rat liver microsomes.	Quinine	54-61	cytochrome P450, family 3, subfamily a, polypeptide 2	Rattus norvegicus	28-34
9260930-10	1997	In voltage-clamped hOCT2-expressing oocytes, inward currents were induced by superfusion with MPP, TEA, choline, quinine, d-tubocurarine, pancuronium, and cyanine863.	Quinine	113-120	solute carrier family 22 member 2	Homo sapiens	19-24
9402622-5	1997	Soa allelic variation had a major effect on sensitivity to 0.003-1.0 mM SOA and several concentrations of the bitter-tasting alkaloids brucine, strychnine, and quinine.	Quinine	160-167	sucrose octaacetate aversion	Mus musculus	0-3
9413916-8	1997	Quinine (Ki = 0.06 microM) and quinidine (Ki = 2.0 microM), selective inhibitors of CYP2D1, competitively inhibited 8-hydroxycarteolol formation.	Quinine	0-7	cytochrome P450, family 2, subfamily d, polypeptide 1	Rattus norvegicus	84-90
9256169-6	1997	The binding of [3H]GBR-12935 to CYP2D6 was decreased partially by substrates or inhibitors of CYP2D isoforms (quinine, quinidine, propranolol, bufuralol, imipramine, and desipramine).	Quinine	110-117	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	32-37
9264312-8	1997	This reaction was negligible in CYP2D6-deficient liver microsomes, was inhibited stereoselectively by the quinidine/quinine enantiomer pair, and was cosegregated with dextromethorphan O-demethylation (r = 0.975).	Quinine	116-123	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	32-38
9088578-11	1997	Competitive inhibition of quinine 3-hydroxylation was observed with a substrate known to be specifically metabolized by human CYP3A, i.e. midazolam, with an apparent Ki value of 11.0 microM.	Quinine	26-33	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	126-131
9833017-2	1997	To determine the impact of impaired AMP metabolism on its behavioural effects, AMP-induced hyperactivity, AMP discrimination and AMP self-administration were examined in male Wistar rats with or without pretreatment with the CYP2D1 inhibitors quinine and budipine.	Quinine	243-250	cytochrome P450, family 2, subfamily d, polypeptide 1	Rattus norvegicus	225-231
9833017-3	1997	In vivo, quinine (20 mg/kg) and budipine (10 mg/kg) increased the plasma area under the curve of AMP 4-fold and 3.6-fold respectively, and decreased the plasma levels of 4-OH-AMP, 3-fold and 8.6-fold, confirming that the doses used suppressed CYP2D1 activity.	Quinine	9-16	cytochrome P450, family 2, subfamily d, polypeptide 1	Rattus norvegicus	243-249
9088578-0	1997	Evidence for involvement of human CYP3A in the 3-hydroxylation of quinine.	Quinine	66-73	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	34-39
9088578-1	1997	AIMS: Our previous studies using in vitro hepatic microsomal preparations suggested that the hepatic metabolism of quinine to form the major metabolite 3-hydroxyquinine is most likely catalysed by human P450 3A (CYP3A).	Quinine	115-122	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	212-217
9088578-12	1997	CONCLUSIONS: The present results strongly indicate that the conversion of quinine to 3-hydroxyquinine is the major metabolic pathway in human liver in vitro and that the reaction is catalysed by CYP3A isoforms.	Quinine	74-81	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	195-200
9088578-2	1997	The present study was carried out to investigate the kinetics and to identify and further characterise the human liver CYP isoforms involved in the metabolism of quinine.	Quinine	162-169	peptidylprolyl isomerase G	Homo sapiens	119-122
9067326-4	1997	In vivo, quinine (20 mg/kg) and budipine (10 mg/kg) produced a marked suppression in brain and plasma hydromorphone levels detected after the peripheral administration of hydrocodone, thus confirming that the doses used suppressed CYP2D1 activity.	Quinine	9-16	cytochrome P450, family 2, subfamily d, polypeptide 1	Rattus norvegicus	231-237
9088578-7	1997	Quinine 3-hydroxylation was inhibited by the specific CYP3A inhibitors, troleandomycin, midazolam and erythromycin.	Quinine	0-7	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	54-59
9105413-7	1997	The contribution of CYP2D1 to the O-dealkylation of EM/NEM and CD/NCD was further confirmed by use of the specific CYP2D1 inhibitors quinine and propafenone.	Quinine	133-140	cytochrome P450, family 2, subfamily d, polypeptide 1	Rattus norvegicus	20-26
9105413-7	1997	The contribution of CYP2D1 to the O-dealkylation of EM/NEM and CD/NCD was further confirmed by use of the specific CYP2D1 inhibitors quinine and propafenone.	Quinine	133-140	cytochrome P450, family 2, subfamily d, polypeptide 1	Rattus norvegicus	115-121
8946502-0	1996	c-Fos induction in the rat nucleus of the solitary tract by intraoral quinine infusion depends on prior contingent pairing of quinine and lithium chloride.	Quinine	70-77	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	0-5
8946502-0	1996	c-Fos induction in the rat nucleus of the solitary tract by intraoral quinine infusion depends on prior contingent pairing of quinine and lithium chloride.	Quinine	126-133	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	0-5
8788453-0	1995	Quinine inhibits release of tumor necrosis factor, apoptosis, necrosis and mortality in a murine model of septic liver failure.	Quinine	0-7	tumor necrosis factor	Mus musculus	28-49
8949984-4	1996	After 24 h incubation with 15 microM of the modulators, MDR1 gene expression was slightly but significantly decreased by two of them, quinine and cyclosporine A, whereas verapamil and S-9788 had very little effect on this parameter.	Quinine	134-141	ATP binding cassette subfamily B member 1	Homo sapiens	56-60
8949984-6	1996	The effect of quinine was studied over a longer time period (4-48 h) and was shown to be maximum at 24 h. These results favor the existence of a direct effect of some MDR reverters, especially quinine, on the expression of the MDR1 gene and could partially explain their modulating effect of MDR.	Quinine	14-21	ATP binding cassette subfamily B member 1	Homo sapiens	227-231
8949984-6	1996	The effect of quinine was studied over a longer time period (4-48 h) and was shown to be maximum at 24 h. These results favor the existence of a direct effect of some MDR reverters, especially quinine, on the expression of the MDR1 gene and could partially explain their modulating effect of MDR.	Quinine	193-200	ATP binding cassette subfamily B member 1	Homo sapiens	227-231
8605869-11	1996	TWIK-1 channel activity is blocked by Ba2+(IC50=100 microM), quinine (IC50=50 microM) and quinidine (IC50=95 microM).	Quinine	61-68	potassium two pore domain channel subfamily K member 1	Homo sapiens	0-6
8788453-3	1995	Pretreatment with quinine, a K+ channel blocker, prevented formation of tumor necrosis factor (TNF) as well as the subsequent hepatic DNA fragmentation and liver enzyme leakage.	Quinine	18-25	tumor necrosis factor	Mus musculus	72-93
7756663-4	1995	Among children receiving quinine and placebo, those with elevated transferrin saturations had a delayed estimated median time to recover full consciousness (68.2 hours) compared with those with saturations &lt; or = 43% (25.4 hours; P = .006).	Quinine	25-32	transferrin	Homo sapiens	66-77
7532036-0	1995	The glycoprotein Ib-IX complex-specific monoclonal antibody SZ1 binds to a conformation-sensitive epitope on glycoprotein IX: implications for the target antigen of quinine/quinidine-dependent autoantibodies.	Quinine	165-172	DLG2 antisense RNA 1	Homo sapiens	60-63
8586645-6	1995	Quinine and quinidine showed 400 and 80 times, respectively, higher affinity for MBP than for debrisoquine 4-hydroxylase.	Quinine	0-7	myelin basic protein	Rattus norvegicus	81-84
8586645-6	1995	Quinine and quinidine showed 400 and 80 times, respectively, higher affinity for MBP than for debrisoquine 4-hydroxylase.	Quinine	0-7	cytochrome P450, family 2, subfamily d, polypeptide 1	Rattus norvegicus	94-120
7532036-1	1995	The monoclonal antibody SZ1 is of interest for two reasons: it was used to define complex formation between glycoprotein (GP) Ib and GP IX, and its epitope is likely to be identical to that recognized by most quinine- and quinidine-dependent autoantibodies that cause thrombocytopenia.	Quinine	209-216	DLG2 antisense RNA 1	Homo sapiens	24-27
7532036-8	1995	Because of the ability of SZ1 to block the binding of many quinine- and quinidine-dependent antibodies, these data strongly suggest that GP IX is the component of the GP Ib-IX complex recognized by those antibodies.	Quinine	59-66	DLG2 antisense RNA 1	Homo sapiens	26-29
7532036-8	1995	Because of the ability of SZ1 to block the binding of many quinine- and quinidine-dependent antibodies, these data strongly suggest that GP IX is the component of the GP Ib-IX complex recognized by those antibodies.	Quinine	59-66	glycoprotein IX platelet	Homo sapiens	137-142
7517207-6	1994	Our findings indicate that DDAb induced by SMX and SIX, in contrast to those induced by quinidine and quinine, are mainly specific for GPIIb/IIIa and react preferentially with calcium-dependent epitopes present only on the intact GPIIb/IIIa heterodimer.	Quinine	102-109	integrin subunit alpha 2b	Homo sapiens	135-140
7712010-15	1995	However, quinine antagonized SCA40 (approximately 2 fold).	Quinine	9-16	coiled-coil domain containing 88C	Homo sapiens	29-34
7712010-16	1995	Nifedipine (1 microM) prevented the antagonism of SCA40 induced by quinine.	Quinine	67-74	coiled-coil domain containing 88C	Homo sapiens	50-55
7514614-11	1994	In conclusion, RVD in THP-1 and HL-60 cells is mediated by independent anion and cation transport mechanisms that involve both a DISA-sensitive anion pathway and a quinine-inhibitable K efflux pathway, neither of which requires increases in intracellular calcium to be activated.	Quinine	164-171	GLI family zinc finger 2	Homo sapiens	22-27
8190753-0	1994	The abnormal quinine drinking aversion in the Brattleboro rat with diabetes insipidus is reversed by the vasopressin agonist DDAVP: a possible role for vasopressin in the motivation to drink.	Quinine	13-20	arginine vasopressin	Rattus norvegicus	105-116
8179913-0	1994	Quinine inhibits production of tumor necrosis factor-alpha from human alveolar macrophages.	Quinine	0-7	tumor necrosis factor	Homo sapiens	31-58
8185638-7	1994	By using quinine as a specific inhibitor of the enzyme, CYP2D1 was identified as an intermediate affinity site in the Wistar strain and was shown to have impaired activity in the DA strain.	Quinine	9-16	cytochrome P450, family 2, subfamily d, polypeptide 1	Rattus norvegicus	56-62
8190753-0	1994	The abnormal quinine drinking aversion in the Brattleboro rat with diabetes insipidus is reversed by the vasopressin agonist DDAVP: a possible role for vasopressin in the motivation to drink.	Quinine	13-20	arginine vasopressin	Rattus norvegicus	152-163
8190753-3	1994	Acute or chronic treatment of BDI rats with desamino-8D arginine vasopressin (DDAVP) restored to normal their drinking response to quinine solution.	Quinine	131-138	arginine vasopressin	Rattus norvegicus	65-76
8190753-6	1994	These results suggest that the abnormal drinking response to quinine-adulterated fluid in BDI rats is reversed by treatment with the vasopressin V2-receptor agonist DDAVP but is unlikely to be a consequence of the restoration of fluid turnover to normal levels by a renal action.	Quinine	61-68	arginine vasopressin receptor 2	Rattus norvegicus	133-156
1449491-4	1992	We developed a method to determine the contents of the H1 receptor and MBP separately using [3H]mepyramine and quinine and found that MBP is abundant in certain areas of bovine brain.	Quinine	111-118	myelin basic protein	Rattus norvegicus	134-137
8006952-12	1994	P2-receptor-stimulated mucin and Isc release was strongly inhibited by a 30 min preincubation with the classical K+ channel blockers quinine (1 mM), quinidine (1 mM), and Ba2+ (3 mM).	Quinine	133-140	LOC100508689	Homo sapiens	23-28
8486572-5	1993	Quinine, at a concentration of 10 mg/L also caused a significant reduction in IFN-gamma and malaria antigen-induced RNI synthesis; this concentration was well within the therapeutic range.	Quinine	0-7	interferon gamma	Mus musculus	78-87
1363199-3	1992	Drug resistance in the cell line RPMI 8226 dox 40, expressing a high level of Pgp, was almost completely reversed by the novel non-immunosuppressive cyclosporin A (CsA) analog SDZ PSC-833 (PSC), while the chemosensitizers verapamil, CsA and quinine, in clinically achievable concentrations, were much less effective.	Quinine	241-248	phosphoglycolate phosphatase	Homo sapiens	78-81
1363199-3	1992	Drug resistance in the cell line RPMI 8226 dox 40, expressing a high level of Pgp, was almost completely reversed by the novel non-immunosuppressive cyclosporin A (CsA) analog SDZ PSC-833 (PSC), while the chemosensitizers verapamil, CsA and quinine, in clinically achievable concentrations, were much less effective.	Quinine	241-248	PSC	Homo sapiens	180-183
1363199-3	1992	Drug resistance in the cell line RPMI 8226 dox 40, expressing a high level of Pgp, was almost completely reversed by the novel non-immunosuppressive cyclosporin A (CsA) analog SDZ PSC-833 (PSC), while the chemosensitizers verapamil, CsA and quinine, in clinically achievable concentrations, were much less effective.	Quinine	241-248	PSC	Homo sapiens	189-192
8289482-0	1994	Comparative effects of quinine and cinchonine in reversing multidrug resistance on human leukemic cell line K562/ADM.	Quinine	23-30	adrenomedullin	Homo sapiens	113-116
8289482-5	1994	Quinine and cinchonine induced both potentiation of doxorubicin, vincristine and mitoxantrone cytotoxicity in K562/ADM cells.	Quinine	0-7	adrenomedullin	Homo sapiens	115-118
1546958-0	1992	Changes in phospholipid metabolism induced by quinine, 4-aminopyridine and tetraethylammonium in the monocytic cell line THP1.	Quinine	46-53	GLI family zinc finger 2	Homo sapiens	121-125
1520054-10	1992	RESULTS: Compared with treatment with placebo, quinine reduced the frequency of cramps and sleep disturbance, but not the average cramp severity.	Quinine	47-54	cathelicidin antimicrobial peptide	Homo sapiens	80-85
1498365-5	1992	Increased extracellular K+ concentrations or K(+)-channel blockers, such as quinine, tetraethylammonium, or barium chloride, inhibited the LPS-stimulated release of TNF alpha, as well as the accumulation of cell-associated TNF alpha as found by enzyme-linked immunosorbent assay analysis, but did not inhibit TNF alpha mRNA accumulation.	Quinine	76-83	tumor necrosis factor	Mus musculus	165-168
1498365-5	1992	Increased extracellular K+ concentrations or K(+)-channel blockers, such as quinine, tetraethylammonium, or barium chloride, inhibited the LPS-stimulated release of TNF alpha, as well as the accumulation of cell-associated TNF alpha as found by enzyme-linked immunosorbent assay analysis, but did not inhibit TNF alpha mRNA accumulation.	Quinine	76-83	tumor necrosis factor	Mus musculus	223-226
1498365-5	1992	Increased extracellular K+ concentrations or K(+)-channel blockers, such as quinine, tetraethylammonium, or barium chloride, inhibited the LPS-stimulated release of TNF alpha, as well as the accumulation of cell-associated TNF alpha as found by enzyme-linked immunosorbent assay analysis, but did not inhibit TNF alpha mRNA accumulation.	Quinine	76-83	tumor necrosis factor	Mus musculus	223-226
1498365-6	1992	Concentrations of quinine (greater than 125 microM) or of enhanced extracellular K+ (25-85 mM) required to inhibit TNF production both significantly depolarized macrophages.	Quinine	18-25	tumor necrosis factor	Mus musculus	115-118
1815219-4	1991	Increasing the dose of NPY also allowed mice to overcome a taste aversion for quinine-adulterated milk.	Quinine	78-85	neuropeptide Y	Mus musculus	23-26
1892858-4	1991	In contrast, the regulatory decrease was inhibited strongly by addition of either 1 mM quinine, 10 microM BAPTA-AM without medium Ca2+, or 0.5 mM DIDS, and partly by either 1 mM EGTA without medium Ca2+, 10 microM trifluoperazine, or substitution of medium Cl- with NO3-.	Quinine	87-94	NBL1, DAN family BMP antagonist	Homo sapiens	266-269
1763518-11	1991	As quinidine is a more potent inhibitor than quinine of debrisoquine 4-hydroxylase in man, the rat should be used only with full realization of its limitations when investigating substrates metabolized by this isoenzyme.	Quinine	45-52	cytochrome P450, family 2, subfamily d, polypeptide 4	Rattus norvegicus	56-82
1913513-0	1991	Sufficient levels of quinine in the serum circumvent the multidrug resistance of the human leukemic cell line K562/ADM.	Quinine	21-28	adrenomedullin	Homo sapiens	115-118
1913513-4	1991	In this report, the efficiency of quinine formiate in reversing the doxorubicin (ADM) (Adriamycin, Adria Laboratories, Columbus, OH) resistance of the well-defined MDR human leukemic cell line K562/ADM was demonstrated.	Quinine	34-41	adrenomedullin	Homo sapiens	81-84
1913513-4	1991	In this report, the efficiency of quinine formiate in reversing the doxorubicin (ADM) (Adriamycin, Adria Laboratories, Columbus, OH) resistance of the well-defined MDR human leukemic cell line K562/ADM was demonstrated.	Quinine	34-41	adrenomedullin	Homo sapiens	198-201
1913513-5	1991	In culture medium, quinine is slightly less effective than verapamil in increasing the cytotoxicity and uptake of ADM when both drugs are used at the same concentration.	Quinine	19-26	adrenomedullin	Homo sapiens	114-117
1913513-7	1991	In patients receiving quinine formiate in a continuous intravenous infusion, a significant correlation (r = 0.84) was found between the serum levels of quinine and the ability of sera to increase ADM uptake in K562/ADM cells.	Quinine	22-29	adrenomedullin	Homo sapiens	196-199
1913513-7	1991	In patients receiving quinine formiate in a continuous intravenous infusion, a significant correlation (r = 0.84) was found between the serum levels of quinine and the ability of sera to increase ADM uptake in K562/ADM cells.	Quinine	22-29	adrenomedullin	Homo sapiens	215-218
1913513-9	1991	At these concentrations, quinine induces a more than double increase in ADM uptake in K562/ADM cells.	Quinine	25-32	adrenomedullin	Homo sapiens	72-75
1913513-9	1991	At these concentrations, quinine induces a more than double increase in ADM uptake in K562/ADM cells.	Quinine	25-32	adrenomedullin	Homo sapiens	91-94
1763518-0	1991	Quinine is a more potent inhibitor than quinidine in rat of the oxidative metabolic routes of methoxyphenamine which involve debrisoquine 4-hydroxylase.	Quinine	0-7	cytochrome P450, family 2, subfamily d, polypeptide 4	Rattus norvegicus	125-151
1671173-6	1991	The resistance conferred by the MDR1 gene can be circumvented in a dose-dependent manner by simultaneous administration of agents previously shown to be inhibitors of the multidrug transporter in vitro, including verapamil isomers, quinidine, and quinine.	Quinine	247-254	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	32-36
1930854-7	1991	In addition, a positive correlation was found between parathyroid hormone and quinine-sensitive K+ efflux in the above ten hypertensives (R = 0.85, P less than .001).	Quinine	78-85	parathyroid hormone	Homo sapiens	54-73
1709374-11	1991	The binding domain(s) on GPIIb/IIIa for the quinine/quinidine-dependent antibodies appear to be sterically close to the epitopes for 22C4 and SZ22.	Quinine	44-51	integrin subunit alpha 2b	Homo sapiens	25-30
1671173-7	1991	Verapamil and quinine, both at levels suitable for human trials that produced only partial sensitization of the MDR1-transgenic mice, were fully sensitizing when used in combination.	Quinine	14-21	ATP binding cassette subfamily B member 1	Homo sapiens	112-116
7835220-7	1994	The main enzyme concerned in the 1- and 8-hydroxylation of both enantiomers is considered to be CYP2D1 from the following observation: the marked strain differences between Sprague-Dawley and Dark Agouti rats and competitive inhibition by quinine.	Quinine	239-246	cytochrome P450, family 2, subfamily d, polypeptide 1	Rattus norvegicus	96-102
2100304-11	1990	Quinine (0.5-2 mM) blocked the outward currents in embryonic cells and Ba2+ (2 mM) blocked both outward and inward currents in neonatal myelinating cells leaving quinine-sensitive outward currents of the embryonic type.	Quinine	162-169	bone area 2	Mus musculus	71-74
1979624-3	1990	Higher quinine (AUC:6470 +/- 1101 vs 3822 +/- 347 ng h mL-1, P less than 0.001) and quinidine (AUC: 6642 +/- 1304 vs 4808 +/- 872 ng h mL-1, P less than 0.05) concentrations were observed during malaria infection (MI).	Quinine	7-14	L1 cell adhesion molecule	Mus musculus	55-59
2363128-0	1990	Expression of the drug-dependent antigen for quinine-dependent antiplatelet antibodies on GP IIIa but not that on GPIb, IIb or IX on human endothelial cells.	Quinine	45-52	integrin subunit beta 3	Homo sapiens	90-97
2363128-3	1990	By immunoblotting of endothelial cells, quinine-dependent IgG binding from four patient sera was observed only to a 93 kDa component corresponding to GP IIIa.	Quinine	40-47	integrin subunit beta 3	Homo sapiens	150-157
2363128-5	1990	Thus endothelial cells express the GP IIIa quinine-dependent epitope on platelet GP IIIa, but not those on other platelet glycoproteins.	Quinine	43-50	integrin subunit beta 3	Homo sapiens	35-42
2363128-5	1990	Thus endothelial cells express the GP IIIa quinine-dependent epitope on platelet GP IIIa, but not those on other platelet glycoproteins.	Quinine	43-50	integrin subunit beta 3	Homo sapiens	81-88
7835228-7	1994	MP metabolism studies were also conducted with CYP2D6 microsomes in the presence of quinidine and quinine.	Quinine	98-105	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	47-53
34959462-3	2021	The present study explored the therapeutic potential of combined treatment with liposomal doxorubicin, P-gp inhibitor quinine, and the photodynamic therapy (PDT) using indocyanine green (ICG) in the adenocarcinoma drug-resistant tumor model.	Quinine	118-125	phosphoglycolate phosphatase	Homo sapiens	103-107
34730282-1	2022	Cerebral malaria patients with polymorphic CYP2C19 genotypes who receive concurrent treatment with quinine are at risk of inadequate or toxic therapeutic drug concentrations due to metabolic drug interactions.	Quinine	99-106	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	43-50
34730282-2	2022	The study aimed to predict the potential dose regimens of quinine when coadministered with phenobarbital in adult patients with cerebral malaria and complications (e.g., lactic acidosis and acute renal failure) and concurrent with seizures and acute renal failure who carry wild-type and polymorphic CYP2C19.	Quinine	58-65	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	300-307
34240224-10	2021	Quinine ameliorated skin damage in the AD-like mice, reduced IgE expression in the blood, inhibited expression of IKKalpha and NF-kappaB, reduced cytokine secretion, reduced KLK7 expression, reduced scratching frequency, increased FLG expression and repaired the skin barrier.	Quinine	0-7	conserved helix-loop-helix ubiquitous kinase	Mus musculus	114-122
34341510-7	2022	Among 6 known K2P channel modulators tested (DCPIB, quinine, fluoxetine, ML365, ML335, and TKDC), ML365 was the most potent TWIK2 channel blocker with an IC50 value of 4.07 +- 1.5 muM.	Quinine	52-59	potassium two pore domain channel subfamily K member 6	Rattus norvegicus	124-129
34240224-10	2021	Quinine ameliorated skin damage in the AD-like mice, reduced IgE expression in the blood, inhibited expression of IKKalpha and NF-kappaB, reduced cytokine secretion, reduced KLK7 expression, reduced scratching frequency, increased FLG expression and repaired the skin barrier.	Quinine	0-7	kallikrein related-peptidase 7 (chymotryptic, stratum corneum)	Mus musculus	174-178
34240224-10	2021	Quinine ameliorated skin damage in the AD-like mice, reduced IgE expression in the blood, inhibited expression of IKKalpha and NF-kappaB, reduced cytokine secretion, reduced KLK7 expression, reduced scratching frequency, increased FLG expression and repaired the skin barrier.	Quinine	0-7	filaggrin	Mus musculus	231-234
35522083-2	2022	We have shown recently that inhibition of CeA/Sst-to-NST neurons increased the ingestion of a normally aversive taste stimulus, quinine HCl (QHCl).	Quinine	141-145	carcinoembryonic antigen gene family	Mus musculus	42-45
35182570-5	2022	During light-induced inhibition of CeA/Sst-to-NST neurons, mice licked significantly more to our three highest concentrations of QHCl compared to control mice, while sucrose intake was unaffected.	Quinine	129-133	carcinoembryonic antigen gene family	Mus musculus	35-38
35182570-5	2022	During light-induced inhibition of CeA/Sst-to-NST neurons, mice licked significantly more to our three highest concentrations of QHCl compared to control mice, while sucrose intake was unaffected.	Quinine	129-133	somatostatin	Mus musculus	39-42
34718440-5	2021	Here, we show reduced quinine aversion and reduced sucrose preference by mice lacking RGS21 does not result from post-ingestive effects, as taste-salient brief-access tests confirm the reduced bitterant aversion and reduced sweetener preference seen using two-bottle choice testing.	Quinine	22-29	regulator of G-protein signalling 21	Mus musculus	86-91
34718440-6	2021	Eliminating Rgs21 expression after chemosensory system development, via tamoxifen-induced Cre recombination in eight week-old mice, led to a reduction in quinine aversive behavior that advanced over time, suggesting that RGS21 functions as a negative regulator to sustain stable bitter tastant reception.	Quinine	154-161	regulator of G-protein signalling 21	Mus musculus	12-17
34718440-6	2021	Eliminating Rgs21 expression after chemosensory system development, via tamoxifen-induced Cre recombination in eight week-old mice, led to a reduction in quinine aversive behavior that advanced over time, suggesting that RGS21 functions as a negative regulator to sustain stable bitter tastant reception.	Quinine	154-161	regulator of G-protein signalling 21	Mus musculus	221-226
35089644-8	2022	RESULTS: The expression of Cx36 was significantly increased in hippocampal neurons of mice exposed to CUMS, while treatment with glycyrrhizinic acid (GZA) or quinine could both down-regulate Cx36 and alleviate depressive-like behaviors.	Quinine	158-165	gap junction protein, delta 2	Mus musculus	27-31
35089644-8	2022	RESULTS: The expression of Cx36 was significantly increased in hippocampal neurons of mice exposed to CUMS, while treatment with glycyrrhizinic acid (GZA) or quinine could both down-regulate Cx36 and alleviate depressive-like behaviors.	Quinine	158-165	gap junction protein, delta 2	Mus musculus	191-195
35522083-3	2022	Because the CeA innervates other forebrain areas such as the lateral hypothalamus (LH) that also sends axonal projections to the NST, the effects on QHCl intake could be, in part, the result of CeA modulation of LH-to-NST neurons.	Quinine	149-153	carcinoembryonic antigen gene family	Mus musculus	194-197